OA19661A

OA19661A - Tablets comprising 2-Hydroxy-6-((2-(1-Isopropyl-1H-Pyrazol-5-YL) Pyridin-3-YL) Methoxy) Benzaldehyde.

Info

Publication number: OA19661A
Application number: OA1201900137
Authority: OA
Inventors: Naveen BEJUGAM; Sean Mark Dalziel; Nazila HABIBIZAD; Ali KOMEYLI; Demei Leung
Original assignee: Global Blood Therapeutics, Inc.
Priority date: 2016-10-12
Filing date: 2017-10-12
Publication date: 2020-12-31

Abstract

Provided herein are high strength/high drug load tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde ("Compound 1"), dispersible tablets comprising Compound 1, processes of manufacturing such tablets, and methods for treating patients with the tablets. Compound 1 is useful for treating hematological disorders such as sickle cell disease, pulmonary disease such as idiopathic pulmonary fibrosis, and hypoxia and hypoxemia conditions.

Description

TABLETS COMPRISING 2-HYDROXY-6-((2-(l-ISOPROPYL-lH-PYRAZOL-5YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit under 35 U.S.C. §119(e) of United States Provisional

Application 62/407,406, filed October 12, 2016, and United States Provisional Application 62/553,716, filed September 1, 2017, which are hereby incorporated by reference in their entireties.

FIELD

[0002] Provided herein are high strength/high drug load tablets comprising 2-hydroxy-6-((2-( 1 isopropyl-lH-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (hereinafter “Compound 1” or “voxelotor”), formulations and compositions of Compound 1, and processes of manufacturing such tablets. The présent disclosure also provides rapidly disintegrating dispersible tablets of Compound 1. Also included are methods of treating patients with the tablets. Compound 1 is useful for treating hematological disorders such as sickle cell disease, pulmonary disease such as idiopathic pulmonary fibrosis, and hypoxia and hypoxemia conditions.

BACKGROUND

[0003] It has been reported that approximately 50% of patients in developed countries do not take 20 their médications as prescribed, that complex drug regimen is a factor contributing to poor médication adhérence, and that adhérence lies between treatment and outcomes.

[0004] Non-adherence to medicines is estimated to cost the health care system $100 billion - $300 billion per year, and numerous studies hâve shown that high rates of non-adherence directly relates to poor clinical outcomes. Further, simple dosing, for example one pill per day, helps maximize adhérence, 25 and medicines that lower the number of pills per day help eliminate some of the known barriers to adhérence.

[0005] Compound 1 is a small molécule active pharmaceutical ingrédient in clinical development stage for the treatment of sickle cell disease, pulmonary disease such as idiopathic pulmonary fibrosis, and hypoxia and hypoxemia conditions. The clinical doses of Compound 1, in adults, can be considered 30 high. Clinical doses include Compound 1 in the range of 500 mg to 1000 mg, or up to 1500 mg, administered orally once a day in either 100 or 300 mg capsules. The high dose 300 mg capsules are Size 0 HPMC capsules and contain over 80% of Compound 1. For example, a size 0 capsule measures 21.6 mm length x 7.64 mm diameter and only 300 mg of Compound 1 drug can be loaded in to such a capsule.

Therefore, for the capsule formulation, 300 mg is the maximum strength feasible due to the density characteristics and the fixed fill volume and dimensions of the Size 0 capsule shell used.

[0006] Thus, there is a need for developing a pharmaceutical formulation containing Compound 1 that is suitable for making alternative dosage forms such as tablets that contain varying amounts of higher doses of Compound 1 to minimize the number of pills to be swallowed by a patient (pill burden) per dose, has suitable size for ease of swallowing, and releases Compound 1 such that it leads to the desired 5 therapeutic effect. Another important advantage of tablet formulations over the capsules is the ability to scale up to commercial volumes and use high speed manufacturing equipment while keeping low cost of goods. The présent disclosure fulfills this and related needs.

SUMMARY

[0007] Provided herein are pharmaceutical compositions that are amenable to large scale manufacturing of high dose (high drug loaded) tablets of Compound 1, including Form II. Such compositions can possess high tablet hardness and low friability, are easily swallowed by patients, and/or release Compound 1 such that it leads to the desired therapeutic effect. Also provided herein are tablets that can provide a wide range of tablet strengths for achieving high dosing requirements and also low 15 dosing needs.

[0008] In a first aspect is a tablet comprising from about 50% to about 70% by weight of Compound 1 and a microcrystalline cellulose as a Aller provided that at least one microcrystalline cellulose is a highcompactable microcrystalline cellulose and wherein the % by weight is relative to the total weight of the tablet.

[0009] Also provided herein are dispersible tablets of Compound 1, wherein the tablet rapidly disintegrates in liquid. In some embodiments, the tablet rapidly disintegrates in less than about 10 mL of liquid. Such tablets can be easily administrated to patients, such as patients between the âges of 9 months old to about 11 years old or patients with difficulty swallowing tablets or capsules.

[0010] Some embodiments herein also provide for methods of treating a condition associated with 25 oxygen deficiency in a patient in need thereof comprising administering to the patient a tablet or dispersible tablet as described herein.

[0011] Also provided herein are methods of making tablets described herein.

BRIEF DESCRIPTION OF THE DRAWINGS

[0012] FIG. 1 shows in vitro dissolution profiles of Form II of Compound 1 tablets G1 and G2, compared to capsule reference product. G1 tablets were at 100 mg strength; G2 tablets were at 100 mg strength and at 300 mg strength with the film coating as per Example 4. Capsules were at 300 mg strength.

[0013] FIG. 2 provides a visual comparison of the size différences between a capsule at 300 mg 35 strength (on the left), a tablet of Compound 1 at 300 mg strength (middle), and a tablet of Compound 1 at 900 mg strength (on the right).

EMBODIMENTS

[0014] In embodiment 1 a, the tablet of the first aspect comprises from about 50% to about 65% by weight of Compound 1. In one embodiment, the tablet comprises Compound 1 in an amount of from 5 about 50% to about 65% by weight of the tablet. In one sub-embodiment of embodiment la, the tablet comprises Compound 1 in an amount about of 65% by weight of the tablet. In a second sub-embodiment of embodiment la, the tablet comprises Compound 1 in an amount of about 60% by weight of the tablet. In a third sub-embodiment of embodiment la, the tablet comprises Compound 1 in an amount of about 60% ± 5% by weight of the tablet. In a fourth sub-embodiment of embodiment la, the tablet comprises 10 Compound 1 in an amount of about 60% ± 2% by weight of the tablet. In a fifth sub-embodiment of embodiment la, the tablet comprises Compound 1 in an amount of about 60% by weight of the tablet.

[0015] In embodiment 1b, the tablet of the first aspect and embodiment la and sub-embodiments contained therein, the tablet comprises a high-compactable microcrystalline cellulose in an amount from about 20% to about 40% by weight of the tablet. In one sub-embodiment of embodiment 1b, the tablet 15 comprises a high-compactable microcrystalline cellulose in an amount of about 30% by weight of the tablet. In another sub-embodiment of embodiment 1b, the tablet comprises a high-compactable microcrystalline cellulose in an amount of about 35% by weight of the tablet. In yet another subembodiment of embodiment 1b, the tablet comprises a high-compactable microcrystalline cellulose in an amount of 35% ± 2% by weight of the tablet. In yet another sub-embodiment of embodiment 1b, the 20 tablet comprises a high-compactable microcrystalline cellulose in an amount of 35% by weight of the tablet. In yet another sub-embodiment of embodiment 1b, the tablet comprises a high-compactable microcrystalline cellulose in an amount of 35% ± 2% by weight of the tablet. In yet another subembodiment of embodiment 1b and sub-embodiments contained therein, the microcrystalline cellulose is a high-compactable microcrystalline cellulose. In yet another sub-embodiment of embodiment 1b and 25 sub-embodiments contained therein, the high-compactable microcrystalline cellulose is Ceolus™ UF-

711. In another sub-embodiment of embodiment 1b and sub-embodiments contained therein, the highcompactable microcrystalline cellulose is Ceolus™ KG-1000 or KG-802.

[0016] In embodiment le, the tablet of the first aspect and embodiments la and 1b and subembodiments contained therein, Compound 1 is a substantially pure crystalline ansolvate form (Form II) 30 characterized by at least two, three, or four X-ray powder diffraction peaks (Cu Ka radiation) selected from 13.37°, 14.37°, 19.95° and 23.92° 20 (each ±0.2 °20). In one embodiment of embodiment le, Compound 1 is 95% in the crystalline ansolvate form characterized by at least two, three, or four X-ray powder diffraction peaks (Cu Ka radiation) selected from 13.37°, 14.37°, 19.95° and 23.92 20 (each ±0.2 °20) and 5% Form I and/or Form N.

[0017] In embodiment Id, the tablet of the first aspect and embodiments la and 1b and subembodiments contained therein, the tablet consists essentially of Compound 1 as a crystalline ansolvate form (Form II) characterized by at least two, three, or four X-ray powder diffraction peaks (Cu Ka radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°2Θ (each ±0.2 °2θ).

[0018] In embodiment le, the tablet of the first aspect, embodiments la, lb, le, and Id, and subembodiments contained therein further comprises a disintegrant wherein the amount of disintegrant is from 0% to about 10% by weight of the tablet. In one subembodiment of embodiment le, the amount of disintegrant is from about 0.75% to about 1.5% by weight of the tablet. In another subembodiment of embodiment le, the amount of disintegrant is from about 1% to about 1.5% by weight of the tablet. In another subembodiment of embodiment le, the amount of disintegrant is 1.25 ± 0.2% by weight of the tablet. In yet another subembodiment of embodiment le, and subembodiments contained therein, the disintegrant is croscarmellose sodium.

[0019] In embodiment If, the tablet of the first, second, third, fourth and fifth aspects, embodiments la, lb, le, Id, and le and sub-embodiments contained therein is, the tablet further comprises a lubricant, wherein the amount of lubricant is from about 1.75% to about 2.75% by weight of the tablet. In one subembodiment of embodiment If, the amount of lubricant is from about 2.0% to about 2.5% by weight of the tablet. In another subembodiment of embodiment If, the amount of lubricant is 2.25 ± 0.2% w/w of the tablet. In another subembodiment of embodiment If, and subembodiments contained therein, the lubricant is magnésium stéarate.

[0020] In embodiment 1g, the tablet of the first aspect, embodiments la and 1 b and subembodiments contained therein further comprises a surfactant wherein the amount of surfactant is from about 1% to about 2% by weight of the tablet. In one subembodiment of embodiment 1g, the amount of surfactant is 1.5 ± 0.2% by weight of the tablet. In another subembodiment of embodiment 1g, and subembodiments contained therein, the surfactant is sodium lauryl sulfate.

[0021] In a second aspect, provided herein is a tablet comprising a granular component wherein the granular component comprises:

(i) about 60% by weight of Compound 1 ;

(ii) a high-compactable microcrystalline cellulose;

(iii) optionally a disintegrant;

(iv) a lubricant;

(v) optionally a surfactant; and (vi) optionally a binder;

wherein the percentage by weight is relative to the total weight of the tablet.

[0022] In embodiment 2a, the granular component of the second aspect comprises:

(i) a high-compactable microcrystalline cellulose in the amount of about 27.50% by weight of the tablet;

(ii) a disintegrant is présent in the amount of about 1% by weight of the tablet; and (iii) a lubricant is présent in the amount of about 1.50% by weight of the tablet.

[0023] In one subembodiment of embodiment 2a:

(i) the amount of high-compactable microcrystalline cellulose is 27.50 ± 2% by weight of the tablet;

(ii) the amount of disintegrant is 1± 0.2% by weight of the tablet; and (iii) the amount of lubricant is 1.50± 0.2% by weight of the tablet.

[0024] In embodiment 2b, the tablet of embodiment 2a and subembodiment thereof the highcompactable microcrystalline cellulose is Ceolus™ UF-711; the disintegrant is croscarmellose sodium, the lubricant is magnésium stéarate and Compound 1 is a substantially pure crystalline ansolvate form characterized by at least two, three or four X-ray powder diffraction peaks (Cu Ka radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°20 (each ±0.2 °20). In one subembodiment of embodiment 2b, Compound 1 is 95% in crystalline ansolvate form characterized by at least two, three, or four X-ray powder diffraction peaks (Cu Ka radiation) selected from 13.37°, 14.37°, 19.95° and 23.92° 20 (each ±0.2 °20) and 5% in Form I and/or Form N; and surfactant is absent.

[0025] In a third aspect, provided herein is a tablet comprising a granular component wherein the granular component consists essentially of:

(i) about 60% by weight of Compound 1 ;

(ii) a high-compactable microcrystalline cellulose;

(iii) optionally a disintegrant;

(iv) a lubricant;

(v) optionally a surfactant; and (vi) optionally a binder;

wherein the percentage by weight is relative to the total weight of the tablet.

[0026] In embodiment 3a, the granular component of the third aspect comprises:

(ii) the disintegrant is présent in the about of about 1% by weight of the tablet; and (iii) the lubricant is présent in the amount of about 1.50% by weight of the tablet; and (iv) optionally about 1.5% by weight a surfactant.

[0027] In one subembodiment of embodiment 3 a:

(ii) the amount of disintegrant is 1 ± 0.2% by weight of the tablet;

(iii) the amount of lubricant is 1.50 ± 0.2% by weight of the tablet; (iv) surfactant is absent.

[0028] In embodiment 3b, the tablet of embodiment 2a and subembodiment thereof the highcompactable microcrystalline cellulose is Ceolus™ UF-711; the disintegrant is croscarmellose sodium, the lubricant is magnésium stéarate and Compound 1 is a substantially pure crystalline ansolvate form characterized by at least two, three or four X-ray powder diffraction peaks (Cu Ka radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°2θ (each ±0.2 °20). In one subembodiment of embodiments 3b, Compound 1 is 95% in crystalline ansolvate form characterized by at least two, three, or four X-ray powder diffraction peaks (Cu Ka radiation) selected from 13.37°, 14.37°, 19.95° and 23.92° 2Θ (each ±0.2 °2θ) and 5% in Form I and/or Form N and the surfactant is absent.

[0029] In embodiment 3c, the tablet of the second and third aspects and embodiments contained therein (e.g., 2a, 2b, 3a and 3b) further comprises an extragranular component.

[0030] In embodiment 3d, the extragranular component of embodiment 3c comprises:

(i) a microcrystalline cellulose;

(ii) a disintegrant;

(iii) optionally a surfactant;

(iv) a lubricant; and (v) optionally a coating;

provided that at least one of intragranular or extragranular component of the tablet contains a surfactant.

[0031] In embodiment 3f, the tablet of embodiments 3d wherein:

(i) the amount of extragranular microcrystalline cellulose is about 7.50% by weight of the tablet;

(ii) the amount of extragranular disintegrant is about 0.25% by weight of the tablet;

(iii) a surfactant is présent in the amount of is about 1.50% by weight of the tablet; and (iv) the amount of extragranular lubricant is about 0.75% by weight of the tablet.

[0032] In embodiment 3g, the tablet of embodiment 3f wherein the microcrystalline cellulose is a high-compactable microcrystalline cellulose selected from Ceolus™ UF-711, Ceolus™ KG-1000 or KG802, preferably Ceolus™ UF-711; the disintegrant is croscarmellose sodium, the lubricant is magnésium stéarate and the surfactant is sodium lauryl sulfate.

[0033] In embodiment 3h, the extragranular component of embodiment 3c consists essentially of: (i) a microcrystalline cellulose;

(ii) a disintegrant;

(iii) optionally a surfactant;

(iv) a lubricant and (v) optionally a coating;

[0034] In embodiment 3i, the tablet of embodiments 3h comprises:

(iii) a surfactant is présent and the amount is about 1.50% by weight of the tablet; and (iv) the amount of extragranular lubricant is about 0.75% by weight of the tablet.

[0035] In embodiment 3j, the tablet of embodiment 3i comprises a microcrystalline cellulose wherein the microcrystalline cellulose a high-compactable microcrystalline cellulose Ceolus™ UF-711; the disintegrant is croscarmellose sodium, the lubricant is magnésium stéarate and the surfactant is 10 sodium lauryl sulfate.

[0036] In embodiment 4, the tablet of the first, second, and third aspects, embodiments la, lb, 3(a-j) and embodiments contained therein the tablet comprises from about 300 mg to about 900 mg of Compound 1.

[0037] In embodiment 4a, the tablet comprises 300 mg, 400 mg, 500 mg, 750 mg, or 900 mg. In one subembodiment of embodiment 4a, the tablet comprises 300 mg of Compound 1. In one subembodiment of embodiment 4a, the tablet comprises 900 mg of Compound 1. In one subembodiment of embodiment 4a, the tablet comprises 1500 mg of Compound 1.

[0038] In another embodiment is a tablet comprising from about 50% to about 70% by weight of Compound 1 and a microcrystalline cellulose as a filler provided that at least one microcrystalline cellulose is a high-compactable microcrystalline cellulose; wherein the % by weight is relative to the total weight of the tablet. In another embodiment is a tablet comprising from about 30% to about 70% by weight of Compound 1 and a microcrystalline cellulose as a filler provided that at least one microcrystalline cellulose is a high-compactable microcrystalline cellulose; wherein the % by weight is relative to the total weight of the tablet.

[0039] In one embodiment, the tablet comprises from about 50% to about 65% by weight of

Compound 1. In one embodiment, the tablet comprises about 65% by weight of Compound 1. In one embodiment, the tablet comprises about 60% by weight of Compound 1. In one embodiment, the tablet comprises about 60% ± 5% by weight of Compound 1. In one embodiment, the tablet comprises about 60 ± 2% by weight of Compound 1. In one embodiment, the tablet comprises about 60% by weight of

Compound 1.

[0040] In another embodiment, the tablet comprises from about 20% to about 40% of a highcompactable microcrystalline cellulose by weight of the tablet. In another embodiment, the tablet comprises about 30% of a high-compactable microcrystalline cellulose by weight of the tablet. In another embodiment, the tablet comprises about 35% of a high-compactable microcrystalline cellulose by weight 35 of the tablet. In yet another embodiment, the tablet comprises about 35 ± 2% of a high-compactable microcrystalline cellulose by weight of the tablet. In yet another embodiment, the tablet comprises about

35% of a high-compactable microcrystalline cellulose by weight of the tablet. In yet another embodiment, the table comprises about 35 ± 2% of a high-compactable microcrystalline cellulose by weight of the tablet. In one embodiment, the microcrystalline cellulose is a high-compactable microcrystalline cellulose. In yet another embodiment the high-compactable microcrystalline cellulose is 5 Ceolus™ UF-711. In another embodiment, the high-compactable microcrystalline cellulose is Ceolus™

KG-1000 or KG-802.

[0041] In another embodiment, the tablet comprises Compound 1 as a substantially pure crystalline ansolvate form characterized by at least two, three, or four X-ray powder diffraction peaks (Cu Ka radiation) selected from 13.37°, 14.37°, 19.95° and 23.92° 20 (each ±0.2 °20). In one embodiment, 10 Compound 1 is 95% crystalline ansolvate form characterized by at least two, three, or four X-ray powder diffraction peaks (Cu Ka radiation) selected from 13.37°, 14.37°, 19.95° and 23.92° 20 (each ±0.2 °20) and 5% Form I and/or Form N.

[0042] In another embodiment, the tablet consists essentially of Compound 1 as a crystalline ansolvate form characterized by at least two, three, or four X-ray powder diffraction peaks (Cu Ka 15 radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°20 (each ±0.2 °20).

[0043] In one embodiment, the tablets described herein further comprise a disintegrant wherein the amount of disintegrant is from 0% to about 10% by weight of the tablet. In one embodiment, the amount of disintegrant is from about 0.75% to about 1.5% by weight of the tablet. In another embodiment, the amount of disintegrant is from about 1% to about 1.5% by weight of the tablet. In another embodiment, 20 the amount of disintegrant is 1.25 ± 0.2% by weight of the tablet. In yet another embodiment, the disintegrant is croscarmellose sodium.

[0044] In another embodiment, the tablets described herein further comprise a lubricant, wherein the amount of lubricant is from about 1.75% to about 2.75% by weight of the tablet. In one embodiment, the amount of lubricant is from about 2.0% to about 2.5% by weight of the tablet. In another embodiment, 25 the amount of lubricant is 2.25 ± 0.2% w/w of the tablet. In another embodiment, the lubricant is magnésium stéarate.

[0045] In another embodiment, the tablets described herein further comprise a surfactant wherein the amount of surfactant is from about 1% to about 2% by weight of the tablet. In one embodiment, the surfactant comprises about 1.5% by weight of the tablet. In one embodiment, the amount of surfactant is 30 1.5 ± 0.2% by weight of the tablet. In another embodiment, the surfactant is sodium lauryl sulfate.

[0046] In another embodiment, the tablets described herein further comprise a glidant, wherein the glidant is in an amount of less than about 2% by weight of the tablet.

[0047] In another aspect, provided herein is a tablet comprising a granular component wherein the granular component comprises:

(i) about 60% by weight of Compound 1 ;

(ii) a high-compactable microcrystalline cellulose;

(iii) optionally a disintegrant;

(iv) a lubricant;

(v) optionally a surfactant; and (vi) optionally a binder;

wherein the percentage by weight is relative to the total weight of the tablet.

[0048] In one embodiment, the granular component comprises:

(ii) a disintegrant in the amount of about 1% by weight of the tablet; and (iii) a lubricant in the amount of about 1.50% by weight of the tablet.

[0049] In one embodiment the granular component comprises:

(i) high-compactable microcrystalline cellulose at an amount of 27.50 ± 2% by weight of the tablet;

(ii) disintegrant at an amount of 1± 0.2% by weight of the tablet; and (iii) lubricant at an amount of 1.50± 0.2% by weight of the tablet.

[0050] In one embodiment, the high-compactable microcrystalline cellulose is Ceolus™ UF-711 ; the disintegrant is croscarmellose sodium, the lubricant is magnésium stéarate and Compound 1 is a substantially pure crystalline ansolvate form characterized by at least two, three or four X-ray powder diffraction peaks (Cu Ka radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°20 (each ±0.2 °20). In one embodiment, Compound 1 is 95% in crystalline ansolvate form characterized by at least two, three, or four X-ray powder diffraction peaks (Cu Ka radiation) selected from 13.37°, 14.37°, 19.95° and 23.92° 20 (each ±0.2 °20) and 5% Form I and/or Form N; and surfactant is absent.

[0051] In another aspect, provided herein is a tablet comprising a granular component consisting essentially of:

(i) about 60% by weight of Compound 1 ;

(ii) a high-compactable microcrystalline cellulose;

(iii) optionally a disintegrant;

(iv) a lubricant;

(v) optionally a surfactant; and (vi) optionally a binder;

wherein the percentage by weight is relative to the total weight of the tablet.

[0052] In one embodiment, the granular component comprises:

(ii) a disintegrant in the amount of about 1% by weight of the tablet;

(iii) a lubricant in the amount of about 1.50% by weight of the tablet; and (iv) optionally about 1.5% by weight a surfactant.

[0053] In one embodiment, the granular component comprises:

(ii) a disintegrant in the amount of about 1% by weight of the tablet;

(iii) a lubricant in the amount of about 1.50% by weight of the tablet; and (iv) optionally a surfactant in the amount of about 1.5% by weight of the tablet.

[0054] In one embodiment, the granular component comprises:

(ii) disintegrant at an amount of 1 ± 0.2% by weight of the tablet;

(iii) lubricant at an amount of 1.50 ± 0.2% by weight of the tablet; and (iv) surfactant is absent.

[0055] In one embodiment, the high-compactable microcrystalline cellulose is Ceolus™ UF-711 ; the disintegrant is croscarmellose sodium, the lubricant is magnésium stéarate; and Compound 1 is a substantially pure crystalline ansolvate form characterized by at least two, three or four X-ray powder diffraction peaks (Cu Ka radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°20 (each ±0.2 °20). In one embodiment, Compound 1 is 95% in crystalline ansolvate form characterized by at least two, three, or four X-ray powder diffraction peaks (Cu Ka radiation) selected from 13.37°, 14.37°, 19.95° and 23.92° 20 (each ±0.2 °20) and 5% Form I and/or Form N and the surfactant is absent.

[0056] In one embodiment, the tablet further comprises an extragranular component.

[0057] In one embodiment, the extragranular component comprises:

(i) a microcrystalline cellulose;

(ii) a disintegrant;

(iii) optionally a surfactant;

(iv) a lubricant; and (v) optionally a coating;

provided that at least one of intragranular or extragranular components of the tablet contains a surfactant.

[0058] In one embodiment, a tablet described herein comprises:

(i) an extragranular microcrystalline cellulose in the amount of about 7.50% by weight of the tablet;

(ii) an extragranular disintegrant in the amount of about 0.25% by weight of the tablet;

(iii) a surfactant in the amount of is about 1.50% by weight of the tablet; and (iv) an extragranular lubricant in the amount of about 0.75% by weight of the tablet.

[00591

In one embodiment, a tablet described herein comprises:

(iii) an extragranular surfactant in the amount of is about 1.50% by weight of the tablet; and (iv) an extragranular lubricant in the amount of about 0.75% by weight ofthe tablet.

[0060] In one embodiment, a tablet described herein comprises:

(i) an extragranular microcrystalline cellulose in the amount of about 5% to about 10% by weight of the tablet;

(ii) an extragranular disintegrant in the amount of about 0.1% to about 0.5% by weight of the tablet;

(iii) a surfactant in the amount of about 1% to about 2% by weight of the tablet; and (iv) an extragranular lubricant in the amount of about 0.5% to about 1% by weight of the tablet.

[0061] In one embodiment, the microcrystalline cellulose is a high-compactable microcrystalline cellulose selected from Ceolus™ UF-711, Ceolus™ KG-1000 or KG-802. In one embodiment, the highcompactable microcrystalline cellulose is Ceolus™ UF-711, the disintegrant is croscarmellose sodium, the lubricant is magnésium stéarate and the surfactant is sodium lauryl sulfate. In one embodiment, the high-compactable microcrystalline cellulose is Ceolus™ UF-711, the disintegrant is croscarmellose sodium, the lubricant is magnésium stéarate, the surfactant is sodium lauryl sulfate, and the glidant is colloïdal Silicon dioxide. In one embodiment, the extragranular microcrystalline cellulose is highcompactable microcrystalline cellulose, the extragranular disintegrant is croscarmellose sodium, the extragranular lubricant is magnésium stéarate; and the extragranular surfactant is présent and is sodium lauryl sulfate. In one embodiment, the high-compactable microcrystalline cellulose is Ceolus™ UF-711.

[0062] In one embodiment, the extragranular component consists essentially of:

(i) a microcrystalline cellulose;

(ii) a disintegrant;

(iii) optionally a surfactant;

(iv) a lubricant; and (v) optionally a coating;

[0063] In one embodiment, the tablets described herein comprise:

(iii) a surfactant in the amount of about 1.50% by weight of the tablet; and (iv) an extragranular lubricant in the amount of about 0.75% by weight of the tablet.

[0064] In one embodiment, a tablet described herein comprises:

[0065] In one embodiment, a tablet described herein comprises:

(ii) an extragranular disintegrant in the amount of about 0.1% to about 0.5% by weight of 15 the tablet;

(iii) a surfactant in the amount of about 1% to about 2% by weight of the tablet;

(iv) an extragranular lubricant in the amount of about 0.5% to about 1% by weight of the tablet; and (vii) optionally a glidant in the amount of less than about 2% by weight of the tablet.

[0066] In one embodiment, the microcrystalline cellulose is a high-compactable microcrystalline cellulose Ceolus™ UF-711; the disintegrant is croscarmellose sodium, the lubricant is magnésium stéarate and the surfactant is sodium lauryl sulfate.

[0067] In one embodiment, the tablets described herein comprise from about 300 mg to about 900 mg of Compound 1.

[0068] In one embodiment, the tablets described herein comprise 300 mg, 400 mg, 500 mg, 750 mg, or 900 mg. In one embodiment, the tablets described herein comprise 300 mg of Compound 1. In one embodiment, the tablets described herein comprise 900 mg of Compound 1.

[0069] In one embodiment, the dispersible tablets described herein comprise:

(i) about 30% to about 70% by weight of Compound 1 ;

(ii) filler;

(iii) disintegrant;

(iv) glidant; and (v) a lubricant;

wherein the percentage by weight is relative to the total weight of the tablet.

[0070] In one embodiment, the dispersible tablets described herein comprise:

(i) about 30% to about 70% by weight of Compound 1 ;

(ii) a filler;

(iii) a disintegrant;

(iv) a glidant;

(v) a lubricant;

(vi) a surfactant; and (vii) optionally a binder;

wherein the amount of disintegrant to filler is in a ratio of about 1:28, and wherein the percentage by weight is relative to the total weight of the tablet.

[0071] In one embodiment, the tablets described herein comprise:

(i) about 30% to about 70% by weight of Compound 1 ;

(ii) a filler;

(iii) less than about 2% by weight of disintegrant;

(iv) a glidant;

(v) a lubricant (vi) a surfactant;, and (vii) optionally a binder;

[0072] In one embodiment, the dispersible tablets described herein comprise:

(i) about 60% by weight of Compound 1 Form II;

(ii) about 20% to about 35% by weight of microcrystalline cellulose;

(iii) about 1% to about 2% by weight of croscarmellose sodium;

(iv) less than about 2% by weight of colloïdal Silicon dioxide;

(v) about 1% to about 5% by weight of magnésium stéarate;

(vi) a sweetener;

(vii) a flavoring agent; and (viii) a coloring agent;

wherein the percentage by weight is relative to the total weight of the tablet and wherein the dispersible tablet disintegrates in a liquid in less than 1 minute.

[0073] In a fourth aspect, provided is a method of increasing affmity of hemoglobin for oxygen in a patient comprising administering to the patient in need thereof a tablet described herein, wherein the tablet comprises a therapeutically effective amount of Compound 1. In one embodiment, the therapeutic amount of Compound 1 is from 50 mg to 2000 mg per day. In one embodiment, the therapeutic amount of Compound 1 is from 600 mg to 2000 mg per day. In one embodiment, the therapeutic amount of

Compound 1 is 600 mg per day. In another embodiment, the therapeutic amount of Compound 1 is 900 mg. In another embodiment the therapeutic amount of Compound 1 is 1500 mg.

[0074] In a fifth aspect, provided is a method for treating a condition associated with oxygen deficiency in a patient having a condition associated with oxygen deficiency. In one embodiment, the 5 method comprises administering to the patient in need thereof a tablet as described herein comprising a therapeutically effective amount of Compound 1. In one embodiment, the condition is sickle cell disease, cancer, a pulmonary disorder such as interstitial pulmonary fibrosis, stroke, high altitude sickness, an ulcer, a pressure sore, acute respiratory disease syndrome, acute lung injury, or a wound. In one embodiment, the condition is idiopathic pulmonary fibrosis. In one embodiment, the therapeutic amount 10 of Compound 1 is from 50 mg to 2000 mg per day. In one embodiment, the therapeutic amount of

Compound 1 is from 600 mg to 2000 mg per day. In one embodiment, the therapeutic amount of Compound 1 is 900 or 1500 mg once a day. In one embodiment, the therapeutic amount of Compound 1 is 600 mg per day. In another embodiment, the therapeutic amount of Compound 1 is 900 mg. In another embodiment the therapeutic amount of Compound 1 is 1500 mg.

DETAILED DESCRIPTION

Définitions

[0075] Unless defined otherwise, ail technical and scientific terms used herein hâve the same meaning as is commonly understood by one of ordinary skill in the art. As used herein, the below terms 20 hâve the following meanings unless specified otherwise. Any methods, devices and materials similar or équivalent to those described herein can be used in the practice of the compositions and methods described herein. The following définitions are provided to facilitate understanding of certain terms used frequently herein and are not meant to limit the scope of the présent disclosure. Ail references referred to herein are incorporated by reference in their entirety.

[0076] Headings used in this application are for reference purposes only and do not in any way limit the présent disclosure.

[0077] It is noted here that as used in this spécification and the appended daims, the singular forms “a” “an” and “the” and the like include plural referents unless the context clearly dictâtes otherwise.

[0078] The term “about” or “approximately” means within ± 30%, 20%, 15%, 10%, 9%, 8%, 7%, 30 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, or 0.05% of a given value or range. In one embodiment, about means ±

5%. In another embodiment, about means ± 4% of a given value or range. In another embodiment, about means ± 3% of a given value or range. In another embodiment, about means ± 2% of a given value or range. In another embodiment, about means ± 1% of a given value or range. In another embodiment, about means ± 0.5% of a given value or range. In another embodiment, about means ± 0.05% of a given 35 value or range.

[0079] It is to be understood that “w/w” refers to the percent weight of an agent or excipient relative to the total weight of the tablet only. Percent weights described herein do not include the weight of coatings as described herein unless explicitly stated as such.

[0080] As used herein “substantially pure” shall refer to ansolvate Form II of Compound 1 associated with about < 10% or Form I and/or Form N, preferably <5% Form I and/or Form N; and most preferably it shall refer to about <2% Form I and/or Form N. When the Form II polymorph of Compound 1 is formulated as a pharmaceutical composition, substantially pure shall preferably refer to about <15% Form I and/or Form N polymorph of Compound 1; preferably, the term shall refer to about <10% Form I and/or Form N polymorph of Compound 1 and more preferably the term shall refer to about <5%

Form I and/or Form N polymorph of Compound 1. Form I of Compound 1 is characterized by X-ray powder diffraction peaks (Cu Ka radiation) at 12.82°, 15.74°, 16.03°, 16.63°, 17.60°, 25.14°, 25.82° and 26.44°2θ (each ±0.2 °2Θ); and Form N of Compound 1 is characterized by X-ray powder diffraction peaks (CuKa radiation) at 11.65°, 11.85°, 12.08°, 16.70°, 19.65° and 23.48°20 (each ±0.2 °20).

[0081] “UF-711” is used in accordance with its ordinary and common usage in the art refers to microcrystalline cellulose (MCC) (Compendial name: microcrystalline cellulose, NF, Ph.Eur., JP Chemical Formula (CôHioOsjn) sold under the trade name CEOLUS®, grade UF-711. UF-711 typically has a powder grade/average particle size of about 50 pm and a bulk density of about 0.2-0.26 g/cm³ (0.22 g/cm³). UF-711 is typically characterized by about a 2% to about a 6% loss on drying and has an angle of repose of about 42 degrees. UF-711 typically has a compactibility index of about 1.5. UF-711 as used herein includes microcrystalline cellulose produced under the CEOLUS UF trademark by Asahi Kasei and any microcrystalline cellulose having substantially similar or identical properties.

[0082] The term “administration” refers to introducing an agent into a patient. A therapeutic amount can be administered, which can be determined by the treating physician or the like. An oral route of administration is preferred. The related terms and phrases administering” and “administration of,” when 25 used in connection with a compound or tablet (and grammatical équivalents) refer both to direct administration, which may be administration to a patient by a medical professional or by selfadministration by the patient, and/or to indirect administration, which may be the act of prescribing a drug. Administration entails delivery to the patient of the drug.

[0083] The “crystalline ansolvate” of 2-hydroxy-6-((2-(l-isopropyl-lH-pyrazol-5-yl)pyridin-330 yl)methoxy)benzaldehyde (Compound 1) is a crystalline solid form of the free base of Compound 1, such as, e.g., crystalline Form I, Form II or Form N as disclosed in International Publication No. WO 2015/120133 Al (see, e.g., pages 3-9 and pages 51-54), the disclosure of which is incorporated herein by reference in its entirety. Compound 1 (also known as “voxelotor”) has the structure:

[0084] “Characterization” refers to obtaining data which may be used to identify a solid form of a compound, for example, to identify whether the solid form is amorphous or crystalline and whether it is unsolvated or solvated. The process by which solid forms are characterized involves analyzing data 5 collected on the polymorphie forms so as to allow one of ordinary skill in the art to distinguish one solid form from other solid forms containing the same material. Chemical identity of solid forms can often be determined with solution-state techniques such as ¹³C NMR or 'H NMR. While these may help identify a material, and a solvent molécule for a solvaté, such solution-state techniques themselves may not provide information about the solid State. There are, however, solid-state analytical techniques that can be used to 10 provide information about solid-state structure and differentiate among polymorphie solid forms, such as single crystal X-ray diffraction, X-ray powder diffraction (XRPD), solid State nuclear magnetic résonance (SS-NMR), and infrared and Raman spectroscopy, and thermal techniques such as differential scanning calorimetry (DSC), Solid State ¹³C-NMR, thermogravimetry (TG), melting point, and hot stage microscopy.

[0085] To “characterize” a solid form of a compound, one may, for example, collect XRPD data on solid forms of the compound and compare the XRPD peaks of the forms. For example, the collection of peaks which distinguish e.g., Form If from the other known forms is a collection of peaks which may be used to characterize Form IL Those of ordinary skill in the art will recognize that there are often multiple ways, including multiple ways using the same analytical technique, to characterize solid forms.

Additional peaks could also be used, but are not necessary, to characterize the form up to and including an entire diffraction pattern. Although ail the peaks within an entire XRPD pattern may be used to characterize such a form, a subset of that data may, and typically is, used to characterize the form.

[0086] An XRPD pattern is an x-y graph with diffraction angle (typically ° 2Θ) on the x-axis and intensity on the y-axis. The peaks within this pattern may be used to characterize a crystalline solid form. 25 As with any data measurement, there is variability in XRPD data. The data are often represented solely by the diffraction angle of the peaks rather than including the intensity of the peaks because peaks intensity can be particularly sensitive to sample préparation (for example, particle size, moisture content, solvent content, and preferred orientation effects influence the sensitivity), so samples of the same material prepared under different conditions may yield slightly different patterns; this variability is usually greater than the variability in diffraction angles. Diffraction angle variability may also be sensitive to sample préparation. Other sources of variability corne from instrument parameters and Processing of the raw X-ray data: different X-ray instruments operate using different parameters and these may lead to slightly different XRPD patterns from the same solid form, and similarly different software packages process X-ray data differently and this also leads to variability. These and other sources of variability are known to those of ordinary skill in the pharmaceutical arts. Due to such sources of variability, it is usual to assign a variability of ±0.2° 2Θ to diffraction angles in XRPD patterns.

[0087] The term “dose” or “dosage” refers to the total amount of active material (e.g., Compound 1 disclosed herein) administered to a patient in a single day (24-hour period). The desired dose may be administered once daily. Altematively, the desired dose may be administered in one, two, three, four or more sub-doses at appropriate intervals throughout the day, where the cumulative amount of the subdoses equals the amount of the desired dose administered in a single day. The terms “dose” and “dosage” 10 are used interchangeably herein.

[0088] As defined herein, where the mass of a Compound 1 is specified, for example, 300 mg or 900 mg of Compound 1, that amount corresponds to the mass of Compound 1 in its free base form in a single tablet.

[0089] The term “hemoglobin” as used herein refers to any hemoglobin protein, including normal 15 hemoglobin (Hb) and sickle hemoglobin (HbS).

[0090] The term “sickle cell disease” refers to diseases mediated by sickle hemoglobin (HbS) that results from a single point mutation in the hemoglobin (Hb). Sickle cell diseases include sickle cell anémia, sickle-hemoglobin C disease (HbSC), sickle beta-plus-thalassaemia (HbS/β ) and sickle betazero- thalassaemia (HbS/βΟ).

[0091] “Therapeutically effective amount” or “therapeutic amount” refers to an amount of a drug or an agent that when administered to a patient suffering from a condition, will hâve the intended therapeutic effect, e.g., alleviation, amelioration, palliation or élimination of one or more manifestations of the condition in the patient. The full therapeutic effect does not necessarily occur by administration of one dose, and may occur only after administration of a sériés of doses and can be administered in one 25 dose form or multiples thereof. For example, 900 mg of the drug can be administered in a single 900 mg strength tablet or three 300 mg strength tablets. Thus, a therapeutically effective amount may be administered in one or more administrations. For example, and without limitation, a therapeutically effective amount of an agent, in the context of treating disorders related to hemoglobin S, refers to an amount of the agent that alleviates, améliorâtes, palliâtes, or éliminâtes one or more manifestations of the 30 disorders related to hemoglobin S in the patient.

[0092] The term “pharmaceutically acceptable” refers to generally safe and non-toxic for in vivo, preferably human, administration.

[0093] The term “patient” refers to a mammal, such as a human, bovine, rat, mouse, dog, monkey, ape, goat, sheep, cow, or deer. A patient as described herein can be a human. In some embodiments, the 35 patient is an adult. In some embodiments, the patient is a child or juvénile. In some embodiments, the patient is about 9 months old to about 11 years old. In some embodiments, the patient is about 9 months old to about 11 years old and has diffïculty swallowing.

[0094] “Treatment,” “treating,” and “treat” are defined as acting upon a disease, disorder, or condition with an agent to reduce or ameliorate the harmful or any other undesired effects of the disease, 5 disorder, or condition and/or its symptoms. Treatment, as used herein, covers the treatment of a human patient, and includes: (a) reducing the risk of occurrence of the condition in a patient determined to be predisposed to the disease but not yet diagnosed as having the condition, (b) impeding the development of the condition, and/or (c) relieving the condition, Le., causing régression of the condition and/or relieving one or more symptoms of the condition. For purposes of treatment of sickle cell disease, 10 bénéficiai or desired clinical results include, but are not limited to, multi-lineage hématologie improvement, decrease in the number of required blood transfusions, decrease in infections, decreased bleeding, and the like. For purposes of treatment of interstitial pulmonary fibrosis, bénéficiai or desired clinical results include, but are not limited to, réduction in hypoxia, réduction in fibrosis, and the like.

[0095] As used herein, “% w/w” refers to the weight of a component based on the total weight of a 15 composition comprising the component. For instance, if component 1 is présent in an amount of 50% in a

100 mg composition, component 1 is présent in an amount of 50 mg. In some embodiments, the composition refers to a formulation as described herein or tablet as described herein.

[0096] As used herein, “rapidly disintegrates” or “rapid disintegration” refers to, in some embodiments, disintegration (of, for example, a tablet as described herein) in a small amount of liquid in 20 less than about 5 minutes, about 4 minutes, about 3 minutes, about 2 minutes, or about 1 minute. In some embodiments, the dispersible tablet disintegrates in a liquid in less than 1 minute. In some embodiments, a dispersible tablet disintegrates in less than about 10 mL, less than about 8 mL, less than about 7 mL, less than about 6 mL, or less than about 5mL of liquid. In some embodiments, a dispersible tablet disintegrates in about 5 mL to about 30 mL, about 5 mL to about 25 mL, or about 5 mL to about 20 mL 25 of liquid. In some embodiments, a dispersible tablet disintegrates in less than about 30 mL or less than about 25 mL of liquid.

Tablets

[0097] Many small molécule active pharmaceutical ingrédients (APIs) can be formulated in low 30 strength tablets because the physicochemical properties of the excipients used in the formulation dominate the properties of the solid composition rather than the physicochemical properties of the APL As the drug load increases the physicochemical properties of the drug substance become progressively dominant in the tablet manufacturing process. Because APIs can hâve a full spectrum of physicochemical properties and are not selected based on physicochemical properties that contribute favorably to the manufacturability and stability of a formulation, it is quite frequent that the physicochemical properties of API présent the largest obstacles to creating a workable high strength formulation.

[0098] Compound 1 is a BCS II compound, where its solubility is the primary biopharmaceutical factor limiting absorption. Compound 1 exists in one form as an ansolvate crystalline form characterized by at least two, three or four X-ray powder diffraction peaks (Cu Ka radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°2Θ (each ±0.2 °20) (see, e.g., PCT application Publication No. WO 2015/120133 Al, incorporated herein by reference in its entirety and for ail purposes). This form can hereinafter also be referred to as Form IL The physicochemical properties of Compound 1, including its Form II, are not as conducive (compared to other drug substances for formulation) to making a high dosage form of Compound 1. For example, Form II of Compound 1 is considered to be poorly water soluble, lipophilie, and has a relatively low melting point. The bulk density of Form II of Compound 1 is considered low and its flowability considered poor. Upon milling, the flowability decreases. The compression characteristics of Form II of Compound 1 are also considered poor, exhibiting low tensile strength which does not increase significantly with compression force. Form II of Compound 1 is also prone to sticking to Steel surfaces, such as in processing equipment for tablet manufacture.

[0099] In addition, another ansolvate crystalline form of Compound 1, referred to as Form N, is known. Form N has an enantiotropic relationship with Form II, with a transition température approximately in the range 30-40 °C. Thus, under températures (e.g. storage) below 40 °C, e.g., at 25 °C, Compound 1 is more thermodynamically stable as Form II and at températures above 40 °C, e.g., at 50 °C, Compound 1 is more thermodynamically stable as Form N. To design tablets containing Compound 1, the above physicochemical property limitations of Compound 1 and the high dose requirements need to be accommodated while ensuring that the tablets hâve dissolution properties that lead to a therapeutic effect.

[0100] Described herein are tablets and dispersible tablets comprising Compound 1. It is also contemplated that the components of these tablets may also be comprised in a composition or a pharmaceutical formulation as described herein. Such compositions may be precursors to the tablets as described herein or may be other formulations known in the art, including, but not limited to, sachets.

[0101] In one embodiment, the tablets described herein comprise Compound 1 as a substantially pure crystalline ansolvate form characterized by at least two X-ray powder diffraction peaks (Cu Ka radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°20 (each ±0.2 °20). In another embodiment, the tablets described herein consists essentially of Compound 1 as a crystalline ansolvate form characterized by at least two X-ray powder diffraction peaks (Cu Ka radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°2θ (each ±0.2 °20). In another embodiment, the crystalline ansolvate form of Compound 1 is characterized by at least three X-ray powder diffraction peaks (Cu Ka radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°20 (each ±0.2 °20).

[0102] In one embodiment, the tablets described herein comprise Compound 1 that is 95% by weight Form II characterized by X-ray powder diffraction peaks (Cu Ka radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°20 (each ±0.2 °20) and 5% by weight Compound 1 is Form I and/or Form N. In certain embodiments, the w/w of Form II to Form I/FormN is 99%/l%; 98%/2%; 97%/3%; 96%/4%,

95%/5%; 94%/6%; 93%/7%; 92%/8%, 91%/9% or 90%/10%. In certain embodiments, the w/w of Form II to Form I/Form N is 99.5%/0.5%; 99.6/0.4%; 99.7%/0.3%; 99.8%/0.2%; 99.9%/0.1%; or 99.95%/0.05%.

[0103] In one embodiment, the tablets described herein comprise Compound 1 that is at least 95% by weight Form II characterized by at least one X-ray powder diffraction peak (Cu Ka radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°20 (each ±0.2 °20). In one embodiment, the tablets described herein comprise Compound 1 that is at least 96% by weight Form II characterized by at least one X-ray powder diffraction peak (Cu Ka radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°20 (each ±0.2 °20). In one embodiment, the tablets described herein comprise Compound 1 that is at least 97% by weight Form II characterized by at least one X-ray powder diffraction peak (Cu Ka radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°20 (each ±0.2 °20). In one embodiment, the tablets described herein comprise Compound 1 that is at least 98% by weight Form II characterized by at least one X-ray powder diffraction peak (Cu Ka radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°20 (each ±0.2 °20). In one embodiment, the tablets described herein comprise Compound 1 that is at least 99% by weight Form II characterized by at least one X-ray powder diffraction peak (Cu Ka radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°20 (each ±0.2 °20).

[0104] In one embodiment, the tablets described herein comprise Compound 1 that is at least 95% by weight Form II characterized by at least two X-ray powder diffraction peaks (Cu Ka radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°20 (each ±0.2 °20). In one embodiment, the tablets described herein comprise Compound 1 that is at least 96% by weight Form II characterized by at least two X-ray powder diffraction peaks (Cu Ka radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°20 (each ±0.2 °20). In one embodiment, the tablets described herein comprise Compound 1 that is at least 97% by weight Form II characterized by at least two X-ray powder diffraction peaks (Cu Ka radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°20 (each ±0.2 °20). In one embodiment, the tablets described herein comprise Compound 1 that is at least 98% by weight Form II characterized by at least two X-ray powder diffraction peaks (Cu Ka radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°20 (each ±0.2 °20). In one embodiment, the tablets described herein comprise Compound 1 that is at least 99% by weight Form II characterized by at least two X-ray powder diffraction peaks (Cu Ka radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°20 (each ±0.2 °20).

[0105] In one embodiment, the tablets described herein comprise Compound 1 that is at least 95% by weight Form II characterized by at least three X-ray powder diffraction peaks (Cu Ka radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°20 (each ±0.2 °20). In one embodiment, the tablets described herein comprise Compound 1 that is at least 96% by weight Form II characterized by at least three X-ray powder diffraction peaks (Cu Ka radiation) selected from 13.37°, 14.37°, 19.95° and

23.92°20 (each ±0.2 °20). In one embodiment, the tablets described herein comprise Compound 1 that is at least 97% by weight Form II characterized by at least three X-ray powder diffraction peaks (Cu Ka radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°20 (each ±0.2 °20). In one embodiment, the tablets described herein comprise Compound 1 that is at least 98% by weight Form II characterized by at least three X-ray powder diffraction peaks (Cu Ka radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°20 (each ±0.2 °20). In one embodiment, the tablets described herein comprise Compound 1 that is at least 99% by weight Form II characterized by at least three X-ray powder diffraction peaks (Cu Ka 5 radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°20 (each ±0.2 °20).

[0106] In one embodiment, the tablets described herein comprise Compound 1 that is at least 95% by weight Form II characterized by X-ray powder diffraction peaks (Cu Ka radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°20 (each ±0.2 °20). In one embodiment, the tablets described herein comprise Compound 1 that is at least 96% by weight Form II characterized by X-ray powder diffraction 10 peaks (Cu Ka radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°20 (each ±0.2 °20). In one embodiment, the tablets described herein comprise Compound 1 that is at least 97% by weight Form II characterized by X-ray powder diffraction peaks (Cu Ka radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°20 (each ±0.2 °20). In one embodiment, the tablets described herein comprise Compound 1 that is at least 98% by weight Form II characterized by X-ray powder diffraction peaks (Cu Ka radiation) 15 selected from 13.37°, 14.37°, 19.95° and 23.92°20 (each ±0.2 °20). In one embodiment, the tablets described herein comprise Compound 1 that is at least 99% by weight Form II characterized by X-ray powder diffraction peaks (Cu Ka radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°20 (each ±0.2 °20). In one embodiment, the tablets described herein comprise Compound 1 that is at least 99.5% by weight Form II characterized by X-ray powder diffraction peaks (Cu Ka radiation) selected from 13.37°, 20 14.37°, 19.95° and 23.92°20 (each ±0.2 °20). In one embodiment, the tablets described herein comprise

Compound 1 that is at least 99.9% by weight Form II characterized by X-ray powder diffraction peaks (Cu Ka radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°20 (each ±0.2 °20).

[0107] The tablets described herein can comprise Compound 1 (e.g. Form I, Form II, or Form N) at an amount of about: 40% to about 80%; 40% to about 70%; 40% to about 60%; 50% to about 80%; 50% 25 to about 70%; or 50% to about 65% w/w. In one embodiment, tablets described herein comprise about

50% to about 70% or about 50% to about 65% w/w of Compound 1. Tablets described herein can comprise at least about: 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95% w/w of Compound 1. Tablets described herein can comprise at least about: 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95% (±2%) w/w of Compound 1. Tablets described herein can comprise 30 at least about: 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95% (±5%) w/w of

Compound 1. In one embodiment, tablets described herein include about: 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95% w/w of Compound 1. In one embodiment, tablets described herein include about: 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95% (±2%) w/w of Compound 1. In one embodiment, tablets described herein include about: 25%, 30%, or 35% w/w of 35 Compound 1. In one embodiment, tablets described herein include about: 25%, 30%, or 35% (±2%) w/w of Compound l.In one embodiment, tablets described herein include about: 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95% (±5%) w/w of Compound 1. In some embodiments, the tablets described herein comprise Compound l (e.g. Form I, Form II, or Form N) at an amount of about: 20% to about 40%; 30% to about 80%; 30% to about 70%; or 30% to about 60% w/w. In some embodiments, the tablets described herein comprise Compound l Form II at an amount of about 30% to about 70% w/w. In some embodiments, the tablets described herein comprise Compound 1 Form II at an amount of about 40% to about 70% w/w.

[0108] The tablets described herein can comprise Compound 1 (e.g. Form I, Form II, or Form N) in an amount of about: 300 mg, 450 mg, 600 mg, 750 mg, 900 mg, 1200 mg, 1500 mg, or 2000 mg. The tablets described herein can comprise Compound 1 (e.g. Form I, Form II, or Form N) in an amount of at least about: 300 mg, 450 mg, 600 mg, 750 mg, 900 mg, 1200 mg, 1500 mg, or 2000 mg. The tablets described herein can comprise Compound 1 (e.g. Form I, Form II, or Form N) in an amount of about: 300 mg, 750 mg, or 900 mg. The tablets described herein can comprise Compound 1 (e.g. Form I, Form II, or Form N) in an amount of about: 300 mg to about 2000 mg; 600 mg to about 2000 mg; or 900 mg to about 1500 mg. In some embodiments, the tablets described herein can comprise Compound 1 (e.g. Form I, Form II, or Form N) in an amount of about 50 mg to about 2000 mg. In some embodiments, the tablets described herein can comprise Compound 1 (e.g. Form I, Form II, or Form N) in an amount of about 50 mg to about 900 mg. In some embodiments, the tablets described herein can comprise Compound 1 (e.g. Form I, Form II, or Form N) in an amount of about 300 mg to about 1500 mg. In some embodiments, the tablets described herein can comprise Compound 1 (e.g. Form I, Form II, or Form N) in an amount of about 900 mg to about 1500 mg. In some embodiments, the tablets described herein can comprise Compound 1 (e.g. Form I, Form II, or Form N) in an amount of about 100 mg to about 600 mg.

[0109] In some embodiments, the tablets described herein can comprise Compound 1 (e.g. Form I, Form II, or Form N) in an amount of about 50 mg. In some embodiments, the tablets described herein can comprise Compound 1 (e.g. Form I, Form II, or Form N) in an amount of about 100 mg. In some embodiments, the tablets described herein can comprise Compound 1 (e.g. Form I, Form II, or Form N) in an amount of about 200 mg. In some embodiments, the tablets described herein can comprise Compound 1 (e.g. Form I, Form II, or Form N) in an amount of about 300 mg. In some embodiments, the tablets described herein can comprise Compound 1 (e.g. Form I, Form II, or Form N) in an amount of about 450 mg. In some embodiments, the tablets described herein can comprise Compound 1 (e.g. Form I, Form II, or Form N) in an amount of about 600 mg. In some embodiments, the tablets described herein can comprise Compound 1 (e.g. Form I, Form II, or Form N) in an amount of about 900 mg.

[0110] In some embodiments, the tablets described herein can comprise Compound 1 Form II in an amount of about 50 mg. In some embodiments, the tablets described herein can comprise Compound 1 Form II in an amount of about 100 mg. In some embodiments, the tablets described herein can comprise Compound 1 Form II in an amount of about 300 mg. In some embodiments, the tablets described herein can comprise Compound 1 Form II in an amount of about 450 mg. In some embodiments, the tablets described herein can comprise Compound 1 Form II in an amount of about 600 mg. In some embodiments, the tablets described herein can comprise Compound 1 Form II in an amount of about 900 mg. In some embodiments, the tablets described herein can comprise Compound l Form II in an amount of about 1500 mg.

[OUI] The tablet of the présent disclosure comprises excipients such as pharmaceutically acceptable filler (also known as diluent), disintegrant, lubricant, and surfactant (also known as a wetting agent). In 5 some embodiments, the tablets described herein further comprise a glidant. Excipients can hâve two or more functions in a pharmaceutical composition. Characterization herein of a particular excipient as having a certain function, e.g·, filler, disintegrant, etc., should not be read as limiting to that function. Further information on excipients can be found in standard reference works such as Handbook of Pharmaceutical Excipients, 3rd ed. (Kibbe, ed. (2000), Washington: American Pharmaceutical

Association). While frequently it is possible for formulators of ordinary skill in the art to interchange one functional excipient in a tablet for an altemate, in the tablet of the présent disclosure, in some embodiments, one of the filler (diluent) has a spécifie requirement to be highly compactable (also referred to herein as highly compressible). High compactibility of such excipients can achieve a high drug load in a single tablet of reasonable size and at suitably high tensile strength to yield a robust tablet that survives pharmaceutical processing, packaging, and handling. An example of such fillers is high compressibility grades of microcrystalline cellulose (MCC). In one embodiment, the drug load of Compound 1 can be maximized by including a high-compactable excipient as described herein.

[0112] Specialty grades of highly compactable MCC are available commercially, such as Ceolus™ UF-711, KG-802, and KG-1000 (e.g. by Asahi Kasei). In one embodiment, the highly compactable MCC 20 is Ceolus™ UF-711. In one embodiment, the highly compactable MCC is KG-802 or KG-1000. In one embodiment, the highly compactable MCC is KG-802. In one embodiment, the highly compactable MCC is KG-1000. In one embodiment, the highly compactable MCC is Ceolus™ UF-711 or an équivalent highly compactable MCC. In one embodiment, the highly compactable MCC is KG-802 or KG-1000 or an équivalent highly compactable MCC. In one embodiment, the highly compactable MCC is KG-802 or 25 an équivalent highly compactable MCC. In one embodiment, the highly compactable MCC is KG-1000 or an équivalent highly compactable MCC.

[0113] In one embodiment, the highly compactable MCC is présent at about: 20% to about 50%; 20% to about 40%; 20 to about 35%; 20% to about 30%; 25% to about 40%; 25% to about 35%; 30% to about 40%; or 30% to about 35% w/w. In one embodiment, the highly compactable MCC is présent at an 30 amount of about: 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% w/w. In one embodiment, the highly compactable MCC is présent at an amount of about: 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% w/w (±2%). In one embodiment, the highly compactable MCC is présent at an amount of about: 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% w/w (±5%).

[0114] In one embodiment, the highly compactable MCC is présent at an amount of at least about: 35 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% w/w. In one embodiment, the highly compactable

MCC is présent at an amount of at least about: 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% w/w (±2%). In one embodiment, the highly compactable MCC is présent at an amount of at least about: 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% w/w (±5%).

[0115] MCC hâve unique particle morphology that can give higher compressibility on a unit mass basis. In one embodiment, tablets described herein comprise UF-711 where the UF-711 increases high drug load tablet of Compound 1 compared to tablets without UF-711. Such tablets can hâve high tablet hardness, and lack difficulty in flowability normally encountered for specialty grades of MCC with high compressibility. Increases in flowability can increase reliability and scalability using dry granulation methods described herein on a commercial manufacturing scale. It was discovered, inter alia, that the high-compactable grade of MCC UF-711 also acts as a binder to hold the granules together. In one embodiment, use of MCC UF-711 obviâtes the need for an additional excipient specifically with binder function, such as hypromellose.

[0116] A comparison of MCC grades is available from the website of Asahi Kasei Ceolus™. Compactibility (used interchangeably with the term compressibility) refers to the extent of plastic deformation the material undergoes upon imposing a mechanical load. At increasing mechanical loads, 15 such as in a hydraulic tablet press, a compressible material will continue to increase in density, as the volume occupied by a given mass is reduced under the load force. Compressible materials yield increasing tensile strength (tablet hardness) as the mechanical load force increases. Incompressible materials reach a plateau in hardness at even low load forces, and the resulting compact or tablet lacks integrity and will fall apart to powder rather than staying intact as a discrète hard compacted mass.

“High-compactable” grades of MCC are considered as those yielding higher compactibility than PH-101 or PH-102 common grades of MCC.

[0117] The compressibility of UF-711 MCC grade is 50% higher than that of conventional PH-101 grade MCC. In addition, using angle of repose as an indicator of flow properties, the UF-711 grade has better flow than PH-101, and flow equally well as PH-102, despite having increased compactibility than 25 either PH-101 or PH-102. This is unexpected since the high compressibility grades of MCC often hâve worse flow properties in exchange for increased compactibility. These two properties of UF-711 were surprisingly useful for Compound 1 high drug load blends and tablets since they facilitate high tablet hardness. In one embodiment, the compactibility of UF-711 allows a greater drug load than otherwise expected. In another embodiment, tablets described herein include pharmaceutical excipients such as 30 fdler(s) and optionally with a glidant and/or binding agent to préparé a mixture that has compressibility and flowability properties similar to those of UF-711 for use in preparing high strength tablets of Compound 1.

[0118] In some embodiments, other grades of microcrystalline cellulose (MCC) known in the art and commercially available can be used. In some embodiments, microcrystalline cellulose (MCC) having 35 a compactability less than UF-711 can be used. In some embodiments, the microcrystalline cellulose is

PH-101, PH-102, PH-103, PH-105, PH-112, PH-113, PH-200, PH-310, or PH-302. In some embodiments, the microcrystalline cellulose is PH-101, PH-102, PH-301, PH-302, PH-200, or UF-702. Other grades of microcrystalline cellulose include various Vivapur® and Emcocel® grades of MCC.

[0119] In some embodiments, the fîller is microcrystalline cellulose, lactose monohydrate, starch, mannitol, sorbitol. dextrose, dibasic calcium phosphate, dicalcium phosphate dihydrate, tricalcium 5 phosphate, calcium phosphate; anhydrous lactose, spray-dried lactose, pregelatinized starch, compressible sugar, such as Di-Pac®(Amstar), hydroxypropyl-methylcellulose, hydroxypropylmethylcellulose acetate stéarate, sucrose-based diluents, confectioner’s sugar, monobasic calcium sulfate monohydrate, calcium sulfate dihydrate, calcium lactate trihydrate, dextrates, hydrolyzed cereal solids, amylose, powdered cellulose, calcium carbonate, glycine, kaolin, mannitol, sodium 10 chloride; inositol, bentonite, or combinations thereof.

[0120] In one embodiment, the fîller is présent at about: 20% to about 50%; 20% to about 40%; 20 to about 35%; 20% to about 30%; 25% to about 40%; 25% to about 35%; 30% to about 40%; or 30% to about 35% w/w. In one embodiment, the fîller is présent at an amount of about: 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% w/w. In one embodiment, the fîller is présent at an amount of about: 10%, 15 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% w/w (±2%). In one embodiment, the fîller is présent at an amount of about: 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% w/w (±5%).

[0121] In one embodiment, the fîller is présent at an amount of at least about: 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% w/w. In one embodiment, the fîller is présent at an amount of at least about: 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% w/w (±2%). In one embodiment, the fîller is 20 présent at an amount of at least about: 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% w/w (±5%).

[0122] The other functional excipients may include dis intégrants, lubricants, surfactants, and binders. In one example such excipients include croscarmellose sodium, magnésium stéarate, and sodium lauryl sulfate, respectively. In one embodiment, such excipients include croscarmellose sodium, magnésium stéarate, colloïdal Silicon dioxide, and sodium lauryl sulfate. Other useful excipients include 25 those described herein, such as a glidant. In one embodiment, tablets described herein comprise a low percent content (e.g. about <1, 2, 3, 4, 5, or 10%) of one or more excipients on a mass basis.

[0123] In certain embodiments, the formulations may also include a disintegrant. A “disintegrant” as used herein refers to an excipient that can breakup or disintegrate the dosage form when it cornes in contact with, for example, the gastrointestinal fluid. Suitable disintegrants include, either individually or 30 in combination, starches including pregelatinized starch and sodium starch glycolate; clays; magnésium aluminum silicate; cellulose-based disintegrants such as powdered cellulose, microcrystalline cellulose, methylcellulose, low-substituted hydroxypropylcellulose, carmellose, carmellose calcium, carmellose sodium and croscarmellose sodium; alginates; povidone; crospovidone; polacrilin potassium; gums such as agar, guar, locust bean, karaya, pectin and tragacanth gums; colloïdal Silicon dioxide; and the like. In 35 one embodiment, the disintegrant is carmellose sodium. In one embodiment, the disintegrant is powdered cellulose, microcrystalline cellulose, methylcellulose, or low-substituted hydroxypropylcellulose, or a ' combination thereof. In one embodiment, the disintegrant is carmellose, carmellose calcium, cannellose sodium or croscarmellose sodium, or a combination thereof. In one embodiment, the disintegrant is croscarmellose sodium. In one embodiment, the disintegrant is colloïdal Silicon dioxide.

[0124] In one embodiment, the disintegrant is présent at an amount of about: 0% to about 10%; 0% 5 to about 5%; 0.5% to about 5%; 0.5% to about 2%; 0.75% to about 2%; 0.75% to about 1.5%; 1 % to about 5%; or 1% to about 1.5% w/w. In one embodiment, the disintegrant is présent at an amount of about 0.25% to about 10%; 0.25% to about 5%; 0.25% to about 4%; 0.25% to about 3.5%; 0.25% to about 3%; 0.25% to about 2.5% w/w, 0.25% to about 2% w/w, or about 0.25% to about 1.5% w/w. In one embodiment, the disintegrant is présent at an amount of about: 0.25%, 0.5%, 0.75%, 1%, 1.25%, 1.5%, 10 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10% w/w. In one embodiment, the disintegrant is présent at an amount of about: 0.25%, 0.5%, 0.75%, 1%, 1.25%, 1.5%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10% (±0.1%) w/w. In one embodiment, the disintegrant is présent at an amount of about: 0.25%, 0.5%, 0.75%, 1%, 1.25%, 1.5%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10% (±0.2%) w/w. In one embodiment, the disintegrant is présent at an amount of at least about: 0.25%, 0.5%, 0.75%, 1%, 1.25%, 1.5%, 2%, 3%, 15 4%, 5%, 6%, 7%, 8%, 9%, or 10% w/w. In one embodiment, the disintegrant is présent at an amount of at least about: 0.25%, 0.5%, 0.75%, 1%, 1.25%, 1.5%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10% (±0.1%) w/w. In one embodiment, the disintegrant is présent at an amount of at least about: 0.25%, 0.5%, 0.75%, 1%, 1.25%, 1.5%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10% (±0.2%) w/w. In such embodiments, the disintegrant can be croscarmellose sodium.

[0125] In certain embodiments, the formulations may include surfactants (also known as wetting agents). Surfactants are normally selected to maintain the drug or drugs in close association with water, a condition that is believed to improve bioavailability of the composition. Non-limiting examples of surfactants that can be used as wetting agents include, either individually or in combination, quatemary ammonium compounds, for example benzalkonium chloride, benzéthonium chloride and cetylpyridinium 25 chloride; dioctyl sodium sulfosuccinate; polyoxyethylene alkylphenyl ethers, for example nonoxynol 9, nonoxynol 10 and octoxynol 9; poloxamers (polyoxyethylene and polyoxypropylene block copolymers); polyoxyethylene fatty acid glycerides and oils, for example polyoxyethylene (8) caprylic/capric monoand diglycerides, polyoxyethylene (35) castor oil and polyoxyethylene (40) hydrogenated castor oil; polyoxyethylene alkyl ethers, for example ceteth-10, laureth-4, laureth-23, oleth-2, oleth-10, oleth-20, 30 steareth-2, steareth-10, steareth-20, steareth-100 and polyoxyethylene (20) cetostearyl ether;

polyoxyethylene fatty acid esters, for example polyoxyethylene (20) stéarate, polyoxyethylene (40) stéarate and polyoxyethylene (100) stéarate; sorbitan esters; polyoxyethylene sorbitan esters, for example polysorbate 20 and polysorbate 80; propylene glycol fatty acid esters, for example propylene glycol laurate; sodium lauryl sulfate; fatty acids and salts thereof, for example oleic acid, sodium oleate and triethanolamine oleate; glyceryl fatty acid esters, for example glyceryl monooleate, glyceryl monostearate and glyceryl palmitostearate; sorbitan esters, for example sorbitan monolaurate, sorbitan monooleate, sorbitan monopalmitate and sorbitan monostearate; tyloxapol; and the like.

[0126] In one embodiment, the surfactant is sodium lauryl sulfate (SLS). In one embodiment, 1.5% of SLS was used. In vitro dissolution and in vivo beagle dog bioavailability studies demonstrated that where 1.5% SLS was included, complété dissolution of Form II of Compound 1 occurred in vitro, and comparable bioavailability in beagle dogs was achieved relative to formulations that lacked high lubricant levels. Therefore, the sticking properties of Form II of Compound 1 can be minimized and/or eliminated with a high level (e.g. greater than about 0.5, 1, 3, or 5%) of magnésium stéarate lubricant. and the potential impact of high lubricant level on drug release was overcome via use of a commonly used surfactant, SLS, at 1.5% w/w, which is an acceptable concentration.

[0127] In one embodiment, the surfactant is présent at an amount of about: 0.5% to about 5%; 0.5% to about 2.5%; 0.5% to about 2%; 1% to about 5%; 1% to about 2.5%; or 1% to about 1.5% w/w. In one embodiments, the surfactant is présent at an amount of about: 0% to about 5%; 0% to about 2%; 0.5% to about 3.5%; 0.5% to about 3%; 0.5% to about 2%; or 0.5% to about 1.5% w/w. In one embodiment, the surfactant is présent at an amount of about 1% to about 2%. In one embodiment, the surfactant is présent at an amount of about: 0.25%, 0.5%, 0.75%, 1%, 1.25%, 1.5%, 2%, 3%, 4%, or 5% w/w. In one embodiment, the surfactant is présent at an amount of about: 0.25%, 0.5%, 0.75%, 1%, 1.25%, 1.5%, 2%, 3%, 4%, or 5% w/w (±0.1%). In one embodiment, the surfactant is présent at an amount of about: 0.25%, 0.5%, 0.75%, 1%, 1.25%, 1.5%, 2%, 3%, 4%, or 5% w/w (±0.2%). In one embodiment, the surfactant is présent at an amount of at least about: 0.25%, 0.5%, 0.75%, 1%, 1.25%, 1.5%, 2%, 3%, 4%, or 5% w/w. In one embodiment, the surfactant is présent at an amount of at least about: 0.25%, 0.5%, 0.75%, 1%, 1.25%, 1.5%, 2%, 3%, 4%, or 5% w/w (±0.1%). In one embodiment, the surfactant is présent at an amount of at least about: 0.25%, 0.5%, 0.75%, 1%, 1.25%, 1.5%, 2%, 3%, 4%, or 5% w/w (±0.2%). In one embodiment, the surfactant is présent at an amount of less than about 5%, less than about 4%, less than about 3%, or less than about 2%. In such embodiments, the surfactant can be SLS. In some embodiments, the formulations described herein do not include a surfactant.

[0128] In certain embodiments, the formulation may contain a lubricant. Lubricants can reduce friction between a tableting mixture and tableting equipment during compression of tablet formulations. Exemplary lubricants include, either individually or in combination, glyceryl behenate; stearic acid and salts thereof, including magnésium, calcium and sodium stéarates; hydrogenated vegetable oils; glyceryl palmitostearate; talc; waxes; sodium benzoate; sodium acetate; sodium fumarate; sodium stearyl fumarate; PEGs (e.g., PEG 4000 and PEG 6000); poloxamers; polyvinyl alcohol; sodium oleate; sodium lauryl sulfate; magnésium lauryl sulfate; and the like. In one embodiment, the lubricant is stearic acid. In one embodiment, the lubricant is magnésium stéarate. In one embodiment, the lubricant is magnésium stéarate présent in the amount of from about 1.75% to about 2.75% by weight of the tablet. In one embodiment, the lubricant is sodium benzoate, sodium acetate, or sodium fumarate. In one embodiment, the lubricant is polyvinyl alcohol. In one embodiment, the lubricant is sodium lauryl sulfate or magnésium lauryl sulfate.

[0129] In one embodiment, the lubricant is présent at an amount of about: 0.5% to about 5%; 0.5% to about 2.5%; 0.5% to about 2%; 1% to about 5%; 1% to about 2.5%; 1% to about 2%; 1.75% to about 2.75%; or 2% to about 2.5% w/w. In one embodiment, the lubricant is présent at an amount of about: 0.5% to about 5%; 0.5% to about 2.75%, or about 0.5% to about 2%. In one embodiment, the lubricant is présent at an amount of about 1.75% to about 2.75%. In one embodiment, the lubricant is présent at an amount of about 0.5% to about 2.75%.In one embodiment, the lubricant is présent at an amount of about: 0.25%, 0.5%, 0.75%, 1%, 1.25%, 1.5%, 2%, 3%, 4%, or 5% w/w. In one embodiment, the lubricant is présent at an amount of about: 0.25%, 0.5%, 0.75%, 1%, 1.25%, 1.5%, 2%, 3%, 4%, or 5% w/w (±0.1%). In one embodiment, the lubricant is présent at an amount of about: 0.25%, 0.5%, 0.75%, 1%, 1.25%, 1.5%, 2%, 3%, 4%, or 5% w/w (±0.2%). In one embodiment, the lubricant is présent at an amount of at least about: 0.25%, 0.5%, 0.75%, 1%, 1.25%, 1.5%, 2%, 3%, 4%, or 5% w/w. In one embodiment, the lubricant is présent at an amount of at least about: 0.25%, 0.5%, 0.75%, 1%, 1.25%, 1.5%, 2%, 3%, 4%, or 5% w/w (±0.1%). In one embodiment, the lubricant is présent at an amount of at least about: 0.25%, 0.5%, 0.75%, 1%, 1.25%, 1.5%, 2%, 3%, 4%, or 5% w/w (±0.2%). In such embodiments, the lubricant can be magnésium stéarate.

[0130] In one embodiment, tablets comprising Form II of Compound 1 comprise a greater level of lubricant (e.g. greater than about 1%) compared to standard tablets. The greater levels of magnésium stéarate lubricant can increase hydrophobicity of pharmaceutical préparations.

[0131] In certain embodiments, the formulation may include a binder. Binding agents or adhesives are useful excipients, particularly where the composition is in the form of a tablet. Such binding agents or adhesives should impart sufficient cohésion to the blend being tableted to allow for normal processing operations such as sizing, lubrication, compression and packaging, but still allow the tablet to disintegrate and the composition to be absorbed upon ingestion. Exemplary binding agents and adhesives include, individually or in combination, acacia; tragacanth; glucose; polydextrose; starch including pregelatinized starch; gelatin; modified celluloses including methylcellulose, carmellose sodium, hydroxypropylmethylcellulose (HPMC or hypromellose), hydroxypropyl-cellulose, hydroxyethylcellulose and ethylcellulose; dextrins including maltodextrin; zein; alginic acid and salts of alginic acid, for example sodium alginate; magnésium aluminum silicate; bentonite; polyethylene glycol (PEG); polyethylene oxide; guar gum; polysaccharide acids; and the like.

[0132] In one embodiment, one or more binding agents, if présent, comprise about 0.1% to about 25%, for example about 0.1% to about 10%, about 0.1% to about 5%, or about 0.1% to about 2%, by weight of the composition. In one embodiment, one or more binding agents, if présent, comprise about: 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10% w/w. In one embodiment, UF-711 is used in a percentage weight disclosed herein and provides granule binding properties sufficient to hold compacts intact through granule milling. Thus, in particular embodiments, tablets described herein include UF-711 in an amount wherein UF-711 acts as a filler and a binder.

[01331 In certain embodiments, the formulation may contain a glidant. Glidants are frequently used to improve flow properties and reduce static in a tableting mixture. Exemplary glidants include, either individually or in combination, colloïdal Silicon dioxide, starch, powdered cellulose, sodium lauryl sulfate, magnésium trisilicate and metallic stéarates. In some embodiments, the glidant is talc. In some embodiments, the glidant is colloïdal Silicon dioxide.

[0134] In one embodiment, one or more glidants, if présent, comprise about 0.1% to about 10%, for example about 0.1% to about 5%, or about 0.1% to about 2%, by weight of the composition. In one embodiment, one or more glidants, if présent, comprise about: 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10% w/w. In one embodiment, one or more glidants, if présent, comprise about 0.01% to about 2% w/w. In some embodiments, the glidant is not more than about 9%, 8%, 7%, 6% or 5% w/w. In some embodiments, the glidant is less than about 3% w/w, 2.5% w/w, or 2% w/w. In some embodiments, the glidant is less than about 2% w/w. In some embodiments, the glidant is in an amount of about 0.75% by weight of the tablet. In one embodiment, the glidant is Talc and colloïdal Silicon dioxide, either individually or in combination. In particular embodiments, tablets described herein do not comprise a glidant or flow aid. In certain embodiments, adéquate blend flowability for purposes of feeding to the compaction zone in, for example, a pharmaceutical roller compaction dry granulation machine during manufacture is obtained in the absence of a glidant or flow aid. In one embodiment, the glidant is added to both the intragranular component and the extrangranular component or to one of the granular components.

[0135] Other excipients such as colorants (coloring agents), coating polymers, flavors (flavoring agents) and sweeteners are known in the pharmaceutical art and can be used in compositions of the présent disclosure. In one embodiment, tablets described herein include a coating surrounding the core described herein comprising Compound 1. Tablets can be coated using formulations known in the art, such as for example, excipients such as talc, polyvinyl alcohol, and PEG (e.g., PEG 4000 and PEG 6000). In some embodiments, the coating polymer can be hydroxypropyl methylcellulose (HPMC). When coated, tablets comprise a core that is coated with a nonfunctional film or a release-modifying or enteric coating.

[0136] In some embodiments, tablets described herein comprise a sweetener (also known as a sweetening agent). In some embodiments, the sweetener may improve the palatability of the tablet by reducing bitterness and thereby improving the acceptability of the formulation for patients, such as a patient about 9 months old to about 11 years old. Non-limiting examples of a sweetener are sucrose, xylitol, maltitol, mannitol, sorbitol, sucralose, sodium saccharin, acesulfame potassium, aspartame, and others known to those skilled in the art. In some embodiments, one or more sweeteners can be used. In some embodiments, the sweetener is sucralose.

[0137] In some embodiments, one or more sweeteners, if présent, comprise about 2% to about 20% or about 0.1% to about 10%, for example about 0.1% to about 5%, or about 0.1% to about 3%, by weight of the composition. In one embodiment, one or more sweeteners, if présent, comprise about: 0.1%, 0.2%,

0.3%, 0.4%, 0.5%, 0.75%, l%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10% w/w.

[0138] Also provided herein are tablets as described herein further comprising a flavoring agent. The flavoring agent may enhance the flavor of the tablet to increase its palatability for patients. A flavoring agent includes but is not limited to Grape, Orange, Cherry, Mango, and Tropical. In some embodiments, a flavoring agent is from an artificial origin, a natural origin, or a combination of natural and artificial origins. In some embodiments, one or more flavoring agents can be used. In some embodiments, the flavoring agent is an artificial grape flavor.

[0139] In some embodiments, one or more flavoring agent, if présent, comprise about 1% to about 5% or about 0.1% to about 10%, for example about 0.1% to about 5%, or about 0.1% to about 3%, by weight of the composition. In one embodiment, one or more flavoring agents, if présent, comprise about: 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10% w/w.

[0140] Also provided herein are tablets as described herein further comprising a coloring agent. Coloring agents may be used to enhance the appearance of the tablet. Non-limiting examples of a coloring agent are dyes and pigments, including but not limited to iron oxide pigment. In some embodiments, the coloring agent is iron oxide yellow.

[0141] In some embodiments, one or more coloring agents, if présent, comprise about 0% to about 1%, 0.1% to about 10%, for example about 0.1% to about 5%, or about 0.1% to about 3%, by weight of the composition. In one embodiment, one or more coloring agents, if présent, comprise about: 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10% w/w.

[0142] Further provided herein is a tablet comprising a granular component wherein the granular component comprises:

(i) about 60% by weight of Compound 1 ;

(ii) a high-compactable microcrystalline cellulose as described herein;

(iii) optionally a disintegrant as described herein;

(iv) a lubricant as described herein;

(v) optionally a surfactant as described herein; and (vi) optionally a binder as described herein;

wherein the percentage by weight is relative to the total weight of the tablet.

[0143] Further provided herein is a tablet comprising a granular component wherein the granular component comprises:

(i) about 60% by weight of Compound 1 ;

(ii) a high-compactable microcrystalline cellulose as described herein;

(iii) optionally a disintegrant as described herein;

(iv) a lubricant as described herein;

(v) optionally a surfactant as described herein;

(vi) optionally a binder as described herein; and (vii) optionally a glidant as described herein;

wherein the percentage by weight is relative to the total weight of the tablet.

[0144] In one embodiment, the granular component comprises:

(i) a high-compactable microcrystalline cellulose as described herein in the amount of about 27.50% by weight of the tablet;

(ii) a disintegrant as described herein is présent in the amount of about 1% by weight of the tablet; and (iii) a lubricant as described herein is présent in the amount of about 1.50% by weight of the tablet.

[0145] In one embodiment, the granular component comprises:

(i) high-compactable microcrystalline cellulose as described herein at an amount of about 27.50 ± 2% by weight of the tablet;

(ii) a disintegrant as described herein at an amount of about 1± 0.2% by weight of the tablet; and (iii) a lubricant as described herein at an amount of about 1.50± 0.2% by weight of the tablet.

[0146] In one embodiment, the intragranular component comprises:

(i) high-compactable microcrystalline cellulose as described herein at an amount of 27% ± 2% by weight of the tablet;

(ii) disintegrant as described herein at an amount of 1%± 0.2% by weight of the tablet;

(iii) lubricant as described herein at an amount of 1.5%± 0.2% by weight of the tablet; and (iv) glidant at an amount of 0.5%± 0.2% by weight of the tablet.

[0147] The high-compactable microcrystalline cellulose of such granular components can be Ceolus™ UF-711. The disintegrant of such granular components can be croscarmellose sodium. The lubricant of such granular components can be magnésium stéarate. Compound 1 of such granular components can be a substantially pure crystalline ansolvate form characterized by at least two, three or four X-ray powder diffraction peaks (Cu Ka radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°2θ (each ±0.2 °20), preferably 2 Compound 1 is 95% in crystalline ansolvate form characterized by at least two, three, or four X-ray powder diffraction peaks (Cu Ka radiation) selected from 13.37°, 14.37°, 19.95° and 23.92° 20 (each ±0.2 °20) and 5% in Form I and/or Form N; and surfactant is absent.

[0148] In some embodiments, the high-compactable microcrystalline cellulose is Ceolus™ UF-711; the disintegrant is croscarmellose sodium; the lubricant is magnésium stéarate; Compound 1 is a substantially pure crystalline ansolvate form characterized by at least two X-ray powder diffraction peaks (Cu Ka radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°20 (each ±0.2 °20); and the surfactant is absent.

[0149] Further provided herein is a tablet comprising a granular component wherein the granular component consists essentially of:

(i) about 60% by weight of Compound 1 ;

(ii) a high-compactable microcrystalline cellulose as described herein;

(iii) optionally a disintegrant as described herein;

(iv) a lubricant as described herein;

wherein the percentage by weight is relative to the total weight of the tablet.

[0150] Further provided herein is a tablet comprising a granular component wherein the granular component consists essentially of:

(i) about 60% by weight of Compound 1 ;

(ii) a high-compactable microcrystalline cellulose as described herein;

(iii) optionally a disintegrant as described herein;

(iv) a lubricant as described herein;

(v) optionally a surfactant as described herein;

(vi) optionally a binder as described herein; and (vii) optionally a glidant;

wherein the percentage by weight is relative to the total weight of the tablet.

[0151] In one embodiment, the granular component comprises:

(ii) a disintegrant as described herein an amount of about 1% by weight of the tablet; and (iii) a lubricant as described herein in an amount of about 1.50% by weight of the tablet; and (iv) optionally about 1.5% by weight of a surfactant as described herein.

[0152] In one embodiment, the granular component comprises:

(i) the amount of high-compactable microcrystalline cellulose is about 27.50% by weight of the tablet;

(ii) the amount of disintegrant is about 1% by weight of the tablet;

(iii) the amount of lubricant is about 1.50% by weight of the tablet; and (iv) optionally, the amount of surfactant is about 1.5% by weight of the tablet.

[0153] In one embodiment, the intragranular component comprises:

(i) a high-compactable microcrystalline cellulose as described herein in the amount of about 27% by weight of the tablet;

(ii) a disintegrant as described herein an amount of about l% by weight of the tablet; and (iii) a lubricant as described herein in an amount of about 1.50% by weight of the tablet;

(iv) optionally about 1.5% by weight of a surfactant as described herein; and (v) optionally about 0.5% by weight of a glidant as described herein.

[0154] In another embodiment, the granular component comprises:

(i) a high-compactable microcrystalline cellulose as described herein in an amount of about 27.50 ± 2% by weight of the tablet;

(ii) a disintegrant as described herein is 1 ± 0.2% by weight of the tablet;

(iii) a lubricant as described herein is 1.50 ± 0.2% by weight of the tablet; and (iv) surfactant as described herein is absent.

[0155] In another embodiment, the intragranular component comprises:

(i) a high-compactable microcrystalline cellulose as described herein in an amount of about 27% ± 2% by weight of the tablet;

(ii) a disintegrant as described herein is 1 ± 0.2% by weight of the tablet;

(iii) a lubricant as described herein is 1.50 ± 0.2% by weight of the tablet;

(iv) surfactant as described herein is absent; and (v) optionally about 0.5% by weight of a glidant as described herein.

[0156] The high-compactable microcrystalline cellulose of such granular components can be Ceolus™ UF-711. The disintegrant of such granular components can be croscarmellose sodium. The lubricant of such granular components can be magnésium stéarate. The Compound 1 of such granular components can be a substantially pure crystalline ansolvate form characterized by at least two, three or four X-ray powder diffraction peaks (Cu Ka radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°20 (each ±0.2 °20), preferably 2 Compound 1 is 95% in crystalline ansolvate form characterized by at least two, three, or four X-ray powder diffraction peaks (Cu Ka radiation) selected from 13.37°, 14.37°, 19.95° and 23.92° 20 (each ±0.2 °20) and 5% in Form I and/or Form N and the surfactant is absent.

[0157] In certain embodiments, the tablets described herein further comprise an extragranular component, which comprises:

(i) a microcrystalline cellulose as described herein;

(ii) a disintegrant as described herein;

(iii) optionally a surfactant as described herein;

(iv) a lubricant as described herein; and (v) optionally a coating as described herein;

provided that at least one of the intragranular or extragranular component of the tablet contains a surfactant.

[0158] In certain embodiments, the tablets described herein further comprise an extragranular component, which comprises:

(i) a microcrystalline cellulose as described herein;

(ii) a disintegrant as described herein;

(iii) optionally a surfactant as described herein;

(iv) a lubricant as described herein;

(v) optionally a coating as described herein; and (vi) optionally a glidant as described herein;

[0159] In certain embodiments, extragranular components described herein do not include

Compound 1.

[0160] In one embodiment, the extragranular component comprises:

(i) an amount of extragranular microcrystalline cellulose as described herein of about

7.50% by weight of the tablet;

(ii) an amount of extragranular disintegrant as described herein of about 0.25% by weight of the tablet;

(iii) a surfactant as described herein in an amount of about 1.50% by weight of the tablet;

and (iv) an amount of extragranular lubricant as described herein of about 0.75% by weight of the tablet.

[0161] In one embodiment, the extragranular component comprises:

7.50% by weight of the tablet;

(iv) an amount of extragranular lubricant as described herein of about 0.75% by weight of the tablet; and (v) optionally a glidant.

[0162] In one embodiment, the extragranular component comprises:

(iii) a surfactant in the amount of about 1% to about 2% by weight of the tablet; and (iv) an extragranular lubricant in the amount of about 0.5% to about l% by weight of the tablet.

[0163] The microcrystalline cellulose of the extragranular component can be a high-compactable microcrystalline cellulose selected from Ceolus™ UF-711, Ceolus™ KG-1000 or KG-802, preferably Ceolus™ UF-711. The disintegrant of the extragranular component can be croscarmellose sodium. The lubricant of the extragranular component can be magnésium stéarate. The surfactant of the extragranular component can be sodium lauryl sulfate.

[0164] In one embodiment, the extragranular component consists essentially of:

(i) a microcrystalline cellulose as described herein;

(ii) a disintegrant as described herein;

(iii) optionally a surfactant as described herein;

provided that at least one ofthe intragranular or extragranular component ofthe tablet contains a surfactant.

[0165] In one embodiment, the extragranular component consists essentially of:

(i) a microcrystalline cellulose as described herein;

(ii) a disintegrant as described herein;

(iii) optionally a surfactant as described herein;

(iv) a lubricant as described herein;

[0166] In one embodiment, the extragranular component comprises:

(i) an amount of extragranular microcrystalline cellulose as described herein of about 7.50% by weight of the tablet;

(iii) a surfactant is présent and the amount as described herein is of about 1.50% by weight of the tablet; and (iv) an amount of extragranular lubricant as described herein of about 0.75% by weight of the tablet.

[0167] In one embodiment, the extragranular component described herein comprises:

(ii) an extragranular disintegrant in the amount of about 0. l% to about 0.5% by weight of the tablet;

[0168] The microcrystalline cellulose of the extragranular component can be a high-compactable microcrystalline cellulose. The microcrystalline cellulose of the extragranular component can be a highcompactable microcrystalline cellulose Ceolus™ UF-711. The disintegrant of the extragranular component can be croscarmellose sodium. The lubricant of the extragranular component can be magnésium stéarate. The surfactant of the extragranular component can be sodium lauryl sulfate.

[0169] Further provided herein is a tablet comprising:

(i) an intragranular component comprising:

(a) 60% by weight of 2-hydroxy-6-((2-(l-isopropyl-lH-pyrazol-5-yl)pyridin-3yl)methoxy)benzaldehyde as a crystalline form characterized by two, three or four X-ray powder diffraction peaks (Cu Ka radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°2θ (each ±0.2 °20);

(b) 27.50% by weight of microcrystalline cellulose Ceolus™ UF-711;

(c) 1.0% by weight of Croscarmellose Sodium; and (d) 1.50% by weight of Magnésium Stéarate; and (ii) an extragranular component comprising:

(a) 9.0% by weight of microcrystalline cellulose Ceolus™ UF-711;

(b) 0.25% by weight of Croscarmellose Sodium; and (c) 0.75% by weight of Magnésium Stéarate;

wherein the percentage by weight is relative to the total weight of the tablet.

[0170] Further provided herein is a tablet comprising:

(i) an intragranular component comprising:

(a) 60% by weight of 2-hydroxy-6-((2-(l-isopropyl-lH-pyrazol-5-yl)pyridin-3yl)methoxy)benzaldehyde as a crystalline form characterized by two, three or four X-ray powder diffraction peaks (Cu Ka radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°20 (each ±0.2 °20);

(b) 27.50% by weight of microcrystalline cellulose Ceolus™ UF-711 ;

(a) 7.50% by weight of microcrystalline cellulose Ceolus™ UF-711;

(b) 0.25% by weight of Croscarmellose Sodium;

(c) 0.75% by weight of Magnésium Stéarate; and (d) 1.50% by weight Sodium Lauryl Sulfate;

wherein the percentage by weight is relative to the total weight of the tablet.

[0171] The tablets described herein having inter-and extragranular components can contain amounts of Compound 1 as described herein (e.g. about 300 mg to about 900 mg; or about 300, 400, 500, 750, or 900 mg).

[0172] Further provided herein is a tablet comprising a granular component wherein the granular component comprises:

(i) about 30% to about 70% by weight of Compound 1 ;

(ii) a filler;

(iii) a disintegrant;

(iv) a glidant;

(v) a lubricant;

(vi) optionally a surfactant; and (vii) optionally a binder;

wherein the percentage by weight is relative to the total weight of the tablet.

[0173] Further provided herein is a tablet comprising a granular component wherein the granular component comprises:

(i) about 60% by weight of Compound 1 ;

(ii) a filler;

(iii) a disintegrant;

(iv) a glidant;

(v) a lubricant;

(vi) optionally a surfactant; and (vii) optionally a binder;

wherein the percentage by weight is relative to the total weight of the tablet.

[0174] Some embodiments provide for a tablet comprising a granular component wherein the granular component comprises:

(i) about 60% by weight of Compound 1 ;

(ii) about 27.5% by weight of filler;

(iii) about 1% by weight of disintegrant;

(iv) about 1.25% by weight of glidant;

(v) about 1.5% by weight of lubricant;

(vi) optionally about 1.5% by weight of surfactant; and (vii) optionally a binder;

wherein the percentage by weight is relative to the total weight of the tablet.

[0175] Some embodiments provide for a tablet comprising a granular component wherein the granular component comprises:

(i) about 60% by weight of Compound 1 ;

(ii) about 27.5% by weight of filler;

(iii) about 1% by weight of disintegrant;

(iv) about 1.25% by weight of glidant;

(v) about 1.5% by weight of lubricant;

(vi) optionally about 2.5% by weight of sweetener;

(vii) optionally about 0.5% by weight of flavoring agent; and (viii) optionally about 0.2% by weight of colorant.

wherein the percentage by weight is relative to the total weight of the tablet.

[0176] In one embodiment, provided herein is a dispersible tablet that comprises:

(i) about 50% to about 70% by weight of Compound 1 ;

(ii) about 20% to about 35% by weight of filler;

(iii) about 1% to about 2% by weight of disintegrant;

(iv) less than about 2% by weight of glidant;

(v) about 1 % to about 5% by weight of lubricant;

(vi) optionally a sweetener;

(vii) optionally a flavoring agent; and (viii) optionally a coloring agent;

wherein the percentage by weight is relative to the total weight of the tablet.

[017 7] In one embodiment, provided herein is a dispersible tablet that comprises:

(i) about 50% to about 70% by weight of Compound 1 ;

(ii) about 20% to about 35% by weight of filler;

(iii) about 1% to about 2% by weight of disintegrant;

(iv) less than about 2% by weight of glidant;

(v) about 1% to about 5% by weight of lubricant;

(vi) optionally about 1% to about 3% by weight of sweetener;

(vii) optionally about 0.2% to about 1.5% by weight of flavoring agent; and (viii) optionally about 0.1% to about 1% by weight of coloring agent;

wherein the percentage by weight is relative to the total weight of the tablet.

[0178] In one embodiment, provided herein is a tablet that comprises:

(i) about 50% to about 65% by weight of Compound 1;

(ii) a filler;

(iii) a surfactant; and (iv) about 0.01% to about 2% by weight of glidant;

wherein the percentage by weight is relative to the total weight of the tablet.

[0179] In one embodiment, provided herein is a tablet that comprises:

(i) about 50% to about 65% by weight of Compound 1;

(ii) about 20% to about 35% by weight of filler;

(iii) about 0.5% to about 2% by weight of surfactant; and (iv) about 0.01% to about 2% by weight of glidant;

wherein the percentage by weight is relative to the total weight of the tablet.

[0180] Also provided herein are dispersible tablets, wherein the tablets rapidly disintegrate in a small amount of liquid for administration to a patient. In some embodiments, tablets described herein may be crushed and mixed with an appropriate vehicle, such as food, for administration to a patient. Tablets as described herein may be useful for pédiatrie patients or patients that hâve difficulty swallowing capsules or tablets.

[0181] In some embodiments, the dispersible tablets provided herein disintegrate in a liquid in less than about 5 minutes, about 4 minutes, about 3 minutes, about 2 minutes, or about 1 minute. In some embodiments, the dispersible tablet disintegrates in a liquid in less than 1 minute.

[0182] In some embodiments, the tablet rapidly disintegrates in less than about 15 mL, about 14 mL, about 13 mL, about 12 mL, about 11 mL, 10 mL, about 9 mL, about 8 mL, about 6 mL, or about 5 mL of liquid. In some embodiments, the tablet rapidly disintegrates in about 10 mL, about 9 mL, about 8 mL, about 6 mL, or about 5 mL of liquid. In some embodiments, the tablet rapidly disintegrates in less than about 5 mL, about 4 mL, or 3 mL of liquid.

[0183] In one embodiment, provided herein is a dispersible tablet comprising:

(i) about 30% to about 70% by weight of Compound 1;

(ii) filler;

(iii) disintegrant;

(iv) glidant; and (v) a lubricant;

wherein the percentage by weight is relative to the total weight of the tablet.

[0184] In one embodiment, provided herein is a dispersible tablet comprising:

(i) about 60% by weight of Compound 1 ;

(ii) filler;

(iii) disintegrant;

(iv) glidant; and (v) a lubricant;

wherein the percentage by weight is relative to the total weight of the tablet.

[0185] In one embodiment, provided herein is a tablet that comprises:

(i) about 30% to about 70% by weight of Compound 1;

(ii) a filler;

(iii) a disintegrant;

(iv) a glidant;

(v) a lubricant;

(vi) a surfactant; and (vii) optionally a binder;

wherein the amount of disintegrant to filler is in a ratio of about 1:28 and wherein the percentage by weight is relative to the total weight of the tablet.

[0186] In one embodiment, provided herein is a tablet that comprises:

(i) about 30% to about 70% by weight of Compound 1;

(ii) a filler;

(iii) less than about 2% by weight of disintegrant;

(iv) a glidant;

(v) a lubricant;

(vi) a surfactant; and (vii) optionally a binder;

[0187] In one embodiment, provided herein is a tablet that comprises:

(i) about 60% by weight of Compound 1 ;

(ii) a filler;

(iii) a disintegrant;

(iv) a glidant;

(v) a lubricant (vi) a surfactant; and (vii) optionally a binder;

[0188] In one embodiment, provided herein is a tablet that comprises:

(i) about 60% by weight of Compound 1 ;

(ii) a filler;

(iii) less than about 2% by weight of disintegrant;

(iv) a glidant;

(v) a lubricant (vi) a surfactant; and (vii) optionally a binder;

[0189] In one embodiment, provided herein is a tablet that comprises:

(i) about 30% to about 70% by weight of Compound 1;

(ii) a filler;

(iii) a disintegrant;

(iv) a lubricant;

(v) a surfactant; and (vi) optionally a binder;

[0190] In one embodiment, provided herein is a tablet that comprises:

(i) about 30% to about 70% by weight of Compound 1;

(ii) a filler;

(iii) less than about 2% by weight of disintegrant;

(iv) a lubricant;

(v) a surfactant; and (vi) optionally a binder;

[0191] In one embodiment, provided herein is a tablet that comprises:

(i) about 60% by weight of Compound 1 ;

(ii) a filler;

(iii) a disintegrant;

(iv) a lubricant;

(v) a surfactant; and (vi) optionally a binder;

[0192] In one embodiment, provided herein is a tablet that comprises:

(i) about 60% by weight of Compound 1 ;

(ii) a filler;

(iii) less than about 2% by weight of disintegrant;

(iv) a lubricant;

(v) a surfactant; and (vi) optionally a binder;

[01931 In some embodiments, the amount of disintegrant to filler is in ratio of about 0:35, 1:60;

about 1:56; about 1:55; about 1:50; about 1:45; about 1:40; about 1:35; about 1:30; about 1:25; about 1:20; about 1:15; about 1:10; about 1:7; and about 1:5. In some embodiments, the amount of disintegrant to filler is in ratio of between about 0:35 to about 1:5. In some embodiments, the amount of disintegrant to filler is in ratio of between about 0:35 to about 1:7. In some embodiments, the amount of disintegrant to filler is in ratio of between about 1:60 to about 1:7. In some embodiments, the amount of disintegrant to filler is in ratio of between about 1:56 to about 1:7. In some embodiments, the amount of disintegrant to filler is in ratio of between about 1:50 to about 1:10. In some embodiments, the amount of disintegrant to filler is in ratio of between about 1:40 to about 1:20. In some embodiments, the amount of disintegrant to filler is in ratio of between about 1:25 to about 1:35. In some embodiments, the amount of disintegrant to filler is in ratio of about 1:30. In some embodiments, the amount of disintegrant to filler is in ratio of about 1:29. In some embodiments, the amount of disintegrant to filler is in ratio of about 1:28. In some embodiments, the amount of disintegrant to filler is in ratio of about 1:27. In some embodiments, the amount of disintegrant to filler is in ratio of about 1:26. In some embodiments, the amount of disintegrant to filler is in ratio of about 1:25.

[0194] In one embodiment, provided herein is a dispersible tablet that comprises:

(i) about 30% to about 70% by weight of Compound 1 ;

(ii) about 20% to about 35% by weight of filler;

(iii) about 1% to about 2% by weight of disintegrant;

(iv) less than about 2% by weight of glidant; and (v) a lubricant;

[0195] In one embodiment, provided herein is a dispersible tablet that comprises:

(i) about 30% to about 70% by weight of Compound 1 ;

(ii) about 20% to about 35% by weight of filler;

(iii) about 1% to about 2% by weight of disintegrant;

(iv) less than about 2% by weight of glidant; and (v) about 1% to about 5% by weight of lubricant;

[0196] In one embodiment, provided herein is a dispersible tablet that comprises:

(i) about 50% to about 70% by weight of Compound 1 ;

(ii) about 20% to about 35% by weight of filler;

(iii) about 1% to about 2% by weight of disintegrant;

(iv) less than about 2% by weight of glidant; and (v) a lubricant;

[0197] In one embodiment, provided herein is a dispersible tablet that comprises:

(i) about 50% to about 70% by weight of Compound 1 ;

(ii) about 20% to about 35% by weight of filler;

(iii) about 1% to about 2% by weight of disintegrant;

[0198] In one embodiment, provided herein is a dispersible tablet that comprises:

(i) about 60% by weight of Compound 1 ;

(ii) about 20% to about 35% by weight of filler;

(iii) about 1% to about 2% by weight of disintegrant;

(iv) less than about 2% by weight of glidant; and (v) a lubricant;

[0199] In one embodiment, provided herein is a dispersible tablet that comprises:

(i) about 60% by weight of Compound 1 ;

(ii) about 20% to about 35% by weight of filler;

(iii) about 1% to about 2% by weight of disintegrant;

[0200] In one embodiment, provided herein is a dispersible tablet that comprises:

(i) about 30% to about 70% by weight of Compound 1;

(ii) about 20% to about 35% by weight of filler;

(iii) about 1% to about 2% by weight of disintegrant;

(iv) less than about 2% by weight of glidant; and (v) a lubricant;

wherein the percentage by weight is relative to the total weight of the tablet.

[0201] In one embodiment, provided herein is a dispersible tablet that comprises:

(i) about 30% to about 70% by weight of Compound 1 ;

(ii) about 20% to about 35% by weight of filler;

(iii) about l% to about 2% by weight of disintegrant;

(iv) less than about 2% by weight of ghdant; and (v) about l% to about 5% by weight of lubricant;

wherein the percentage by weight is relative to the total weight of the tablet.

[0202] In one embodiment, provided herein is a dispersible tablet that comprises:

(i) about 50% to about 70% by weight of Compound 1;

(ii) about 20% to about 35% by weight of fîller;

(iii) about 1% to about 2% by weight of disintegrant;

(iv) less than about 2% by weight of glidant; and (v) a lubricant;

wherein the percentage by weight is relative to the total weight of the tablet.

[0203] In one embodiment, provided herein is a dispersible tablet that comprises:

(i) about 50% to about 70% by weight of Compound 1 ;

(ii) about 20% to about 35% by weight of fîller;

(iii) about 1% to about 2% by weight of disintegrant;

wherein the percentage by weight is relative to the total weight of the tablet.

[0204] In one embodiment, provided herein is a dispersible tablet that comprises:

(i) about 60% by weight of Compound 1 ;

(ii) about 20% to about 35% by weight of fîller;

(iii) about 1% to about 2% by weight of disintegrant;

(iv) less than about 2% by weight of glidant; and (v) a lubricant;

wherein the percentage by weight is relative to the total weight of the tablet.

[0205] In one embodiment, provided herein is a dispersible tablet that comprises:

(i) about 60% by weight of Compound 1 ;

(ii) about 20% to about 35% by weight of fîller;

(iii) about 1% to about 2% by weight of disintegrant;

(iv) less than about 2% by weight of glidant; and (v) about 1 % to about 5% by weight of lubricant;

wherein the percentage by weight is relative to the total weight of the tablet.

[0206] In some embodiments, the dispersible tablet further comprises a sweetener, a colorant, a flavoring agent, or a combination thereof.

[0207] In one embodiment, provided herein is a dispersible tablet that comprises:

(i) about 30% to about 70% by weight of Compound 1 ;

(ii) about 20% to about 35% by weight of filler;

(iii) about 1% to about 2% by weight of disintegrant;

(iv) less than about 2% by weight of glidant;

(v) a lubricant;

(vi) a sweetener;

(vii) a flavoring agent; and (viii) a coloring agent;

[0208] In one embodiment, provided herein is a dispersible tablet that comprises:

(i) about 50% to about 70% by weight of Compound 1;

(ii) about 20% to about 35% by weight of filler;

(iii) about 1% to about 2% by weight of disintegrant;

(iv) less than about 2% by weight of glidant;

(v) a lubricant;

(vi) a sweetener;

(vii) a flavoring agent; and (viii) a coloring agent;

[0209] In one embodiment, provided herein is a dispersible tablet that comprises:

(i) about 60% by weight of Compound 1 ;

(ii) about 20% to about 35% by weight of filler;

(iii) about 1% to about 2% by weight of disintegrant;

(iv) less than about 2% by weight of glidant;

(v) a lubricant;

(vi) a sweetener;

(vii) a flavoring agent; and (viii) a coloring agent;

[0210] In one embodiment, provided herein is a dispersible tablet that comprises:

(i) about 60% by weight of Compound 1 Form II;

(ii) about 20% to about 35% by weight of filler;

(iii) about 1% to about 2% by weight of disintegrant;

(iv) less than about 2% by weight of glidant;

(v) about 1% to about 5% by weight of lubricant;

(vi) a sweetener;

(vii) a flavoring agent; and (viii) a coloring agent;

wherein the percentage by weight is relative to the total weight of the tablet and wherein the dispersible tablet disintegrates in a liquid in less than l minute.

[0211] In one embodiment, provided herein is a dispersible tablet that comprises:

(i) about 60% by weight of Compound 1 Form II;

(ii) about 20% to about 35% by weight of filler;

(iii) about 1% to about 2% by weight of disintegrant;

(iv) less than about 2% by weight of glidant;

(v) about 1% to about 5% by weight of lubricant;

(vi) about 1% to about 3% by weight of sweetener;

(vii) about 0.2% to about 1.5% by weight of flavoring agent; and (viii) about 0.1% to about 1% by weight of coloring agent;

[0212] In one embodiment, provided herein is a dispersible tablet that comprises:

(i) about 60% by weight of Compound 1 Form II;

(ii) about 20% to about 35% by weight of microcrystalline cellulose;

(iii) about 1% to about 2% by weight of croscarmellose sodium;

(iv) less than about 2% by weight of colloïdal Silicon dioxide;

(v) about 1% to about 5% by weight of magnésium stéarate;

(vi) a sweetener;

(vii) a flavoring agent; and (viii) a coloring agent;

[0213] In one embodiment, provided herein is a dispersible tablet that comprises:

(i) about 60% by weight of Compound 1 Form II;

(ii) about 20% to about 35% by weight of microcrystalline cellulose;

(iii) about 1% to about 2% by weight of croscarmellose sodium;

(iv) less than about 2% by weight of colloïdal Silicon dioxide;

(v) about 1% to about 5% by weight of magnésium stéarate;

(vi) sucralose;

(vii) artificial grape flavor; and (viii) iron oxide pigment;

[0214] In one embodiment, provided herein is a dispersible tablet that comprises:

(i) about 60% by weight of Compound 1 Form II;

(ii) about 20% to about 35% by weight of microcrystalline cellulose;

(iii) about 1% to about 2% by weight of croscarmellose sodium;

(iv) less than about 2% by weight of colloïdal Silicon dioxide;

(v) about 1% to about 5% by weight of magnésium stéarate;

(vi) about 1% to about 3% by weight of sweetener;

(vii) about 0.2% to about 1.5% by weight of flavoring agent; and (viii) about 0.1% to about 1 % by weight of coloring agent;

[0215] In one embodiment, provided herein is a dispersible tablet that comprises:

(i) about 60% by weight of Compound 1 Form II;

(ii) about 20% to about 35% by weight of microcrystalline cellulose;

(iii) about 1% to about 2% by weight of croscarmellose sodium;

(iv) less than about 2% by weight of colloïdal Silicon dioxide;

(v) about 1 % to about 5% by weight of magnésium stéarate;

(vi) about 1% to about 3% by weight of sucralose;

(vii) about 0.2% to about 1.5% by weight of artificial grape flavor; and (viii) about 0.1% to about 1% by weight of iron oxide pigment;

[0216] In one embodiment, provided herein is a dispersible tablet that comprises:

(i) about 30% to about 70% by weight of Compound 1 ;

(ii) about 20% to about 35% by weight of filler;

(iii) about 1 % to about 2% by weight of disintegrant;

(iv) less than about 2% by weight of glidant;

(v) a lubricant;

(vi) a sweetener;

(vii) a flavoring agent; and (viii) a coloring agent;

wherein the percentage by weight is relative to the total weight of the tablet.

[0217] In one embodiment, provided herein is a dispersible tablet that comprises:

(i) about 50% to about 70% by weight of Compound 1 ;

(ii) about 20% to about 35% by weight of filler;

(iii) about l% to about 2% by weight of disintegrant;

(iv) less than about 2% by weight of glidant;

(v) a lubricant;

(vi) a sweetener;

(vii) a flavoring agent; and (viii) a coloring agent;

wherein the percentage by weight is relative to the total weight of the tablet.

[0218] In one embodiment, provided herein is a dispersible tablet that comprises:

(i) about 60% by weight of Compound 1 ;

(ii) about 20% to about 35% by weight of filler;

(iii) about 1% to about 2% by weight of disintegrant;

(iv) less than about 2% by weight of glidant;

(v) a lubricant;

(vi) a sweetener;

(vii) a flavoring agent; and (viii) a coloring agent;

wherein the percentage by weight is relative to the total weight of the tablet.

[0219] In one embodiment, provided herein is a dispersible tablet that comprises:

(i) about 60% by weight of Compound 1 Form II;

(ii) about 20% to about 35% by weight of filler;

(iii) about 1% to about 2% by weight of disintegrant;

(iv) less than about 2% by weight of glidant;

(v) about 1% to about 5% by weight of lubricant;

(vi) a sweetener;

(vii) a flavoring agent; and (viii) a coloring agent;

wherein the percentage by weight is relative to the total weight of the tablet.

[0220] In one embodiment, provided herein is a dispersible tablet that comprises:

(i) about 60% by weight of Compound 1 Form II;

(ii) about 20% to about 35% by weight of filler;

(iii) about 1% to about 2% by weight of disintegrant;

(iv) less than about 2% by weight of glidant;

(v) about 1% to about 5% by weight of lubricant;

(vi) about 1% to about 3% by weight of sweetener;

wherein the percentage by weight is relative to the total weight of the tablet.

[0221] In one embodiment, provided herein is a dispersible tablet that comprises:

(i) about 60% by weight of Compound 1 Form II;

(ii) about 20% to about 35% by weight of microcrystalline cellulose;

(iii) about 1% to about 2% by weight of croscarmellose sodium;

(iv) less than about 2% by weight of colloïdal Silicon dioxide;

(v) about 1% to about 5% by weight of magnésium stéarate;

(vi) a sweetener;

(vii) a flavoring agent; and (viii) a coloring agent;

wherein the percentage by weight is relative to the total weight of the tablet.

[0222] In one embodiment, provided herein is a dispersible tablet that comprises:

(i) about 60% by weight of Compound 1 Form II;

(ii) about 20% to about 35% by weight of microcrystalline cellulose;

(iii) about 1% to about 2% by weight of croscarmellose sodium;

(iv) less than about 2% by weight of colloïdal Silicon dioxide;

(v) about 1% to about 5% by weight of magnésium stéarate;

(vi) about 1% to about 3% by weight of sweetener;

(vii) about 0.2% to about 1.5% by weight of a flavoring agent; and (viii) about 0.1% to about 1% by weight of a coloring agent;

wherein the percentage by weight is relative to the total weight of the tablet.

[0223] In one embodiment, provided herein is a dispersible tablet that comprises:

(i) about 60% by weight of Compound 1 Form II;

(ii) about 20% to about 35% by weight of microcrystalline cellulose;

(iii) about 1% to about 2% by weight of croscarmellose sodium;

(iv) less than about 2% by weight of colloïdal Silicon dioxide;

(v) about 1% to about 5% magnésium stéarate;

(vi) sucralose;

(vii) artificial grape flavor; and (viii) iron oxide pigment;

wherein the percentage by weight is relative to the total weight of the tablet.

[0224] In one embodiment, provided herein is a dispersible tablet that comprises:

(i) about 60% by weight of Compound 1 Form II;

(ii) about 20% to about 35% by weight of microcrystalline cellulose;

(iii) about 1% to about 2% by weight of croscarmellose sodium;

(iv) less than about 2% by weight of colloïdal Silicon dioxide;

(v) about 1% to about 5% magnésium stéarate;

(vi) about 1% to about 3% by weight of sucralose;

(vii) about 0.2% to about 1.5% by weight of artificial grape flavor; and (viii) about 0.1% to about 1% by weight of iron oxide pigment; wherein the percentage by weight is relative to the total weight of the tablet.

[0225] In one embodiment, provided herein is a dispersible tablet that comprises:

(i) an intragranular component comprising:

(a) about 58% by weight of Compound 1 Form II;

(b) about 26% by weight of microcrystalline cellulose;

(c) about 1% by weight of croscarmellose sodium;

(d) about 1.5% by weight of magnésium stéarate;

(e) about 0.5% by weight of colloïdal Silicon dioxide; and (ii) an extragranular component comprising:

(a) about 8% by weight of microcrystalline cellulose;

(b) about 0.25% by weight of croscarmellose sodium;

(c) about 0.8% by weight of magnésium stéarate;

(d) about 2.5% by weight of sucralose;

(g) about 0.5% by weight of artificial grape flavor;

(h) about 0.2% by weight of iron oxide pigment; and (vi ii) about 0.2% by weight of colloïdal Silicon dioxide;

wherein the percentage by weight is relative to the total weight of the tablet.

Manufacturing Processes

[0226] In one aspect, the tablets of the présent disclosure can be prepared by dry granulation process. In one embodiment, the dry granulation process comprises: mixing Compound 1 with excipients and compacting the mix to form a compact mass. In another embodiment the compacts are milled to form dense flowable granules. The granular product is admixed with an extragranular component and compressed into tablets. Compaction can be done by conventional equipment. In one embodiment, the blended API and excipients are passed through a roller compacter, for example a Gerteis Minipactor, or Gerteis Macropactor, for compaction.

[0227] In one embodiment, a grade of MCC that increases the overall blend compressibility can yield drug loadings (w/w) of about: 40%-80%, 50%-80%, or 50%-70%. In one embodiment, a grade of MCC that increases the overall blend compressibility can yield drug loadings (w/w) of about: 40%, 50%, 55%, 60%, 65%, 66%, 68%, 70%, 72%, 75%, 80%, or more. In one embodiment, a grade of MCC that increases the overall blend compressibility can yield drug loadings (w/w) of at least: 40%, 50%, 55%, 60%, 65%, 66%, 68%, 70%, 72%, 75%, 80%, or more. Such drug yields can be useful in scalable manufacturing manner, e.g., adéquate for large scale manufacturing purposes, in particular high tablet hardness and low friability.

[0228] In one embodiment, the tablets described herein include a drug loading of about 60%. At

60% load, 300 mg Form II of Compound 1 can be delivered from a 500 mg total tablet core weight. In one embodiment, the tablet is sufficiently sized to permit patients to swallow the tablet without difficulty. The dry granulation process described herein can be used to manufacture tablets comprising varying amounts of Compound 1. For example, the common blend can be tableted at to produce 300 mg, 600 mg, or 900 mg tablets. For a 900 mg tablet, a 1,500 mg total tablet core weight is needed. In some embodiments, for a 900 mg tablet, a 1,500 mg or 1,511 mg total tablet core weight is needed. In one embodiment, the tablet is sufficiently sized to permit patients to swallow the tablet without difficulty. In one embodiment, the tablets described herein provide advantages for ease of administration by patients over other dosages and dosage forms, which may resuit in increased patient compliance and clinical outcomes.

[0229] In some embodiments, the tablets described herein can be prepared by a wet granulation process. Wet granulation includes but is not limited to high/low shear wet granulation and fluid bed granulation. In some embodiments, Compound 1 and excipients (e.g., binder, disintegrant, surfactant, sweeteners, flavoring agents, and/or other excipients) are processed in a wet granulator and subsequently dried. The resulting granules are sized through a milling process, then blended with glidants and/or lubricants.

[0230] Varions compression forces can be used to produce the tablets. The selected force used to compress tablets described herein meets the USP requirements for disintegration time. In some embodiments, the selected force for compression of a dispersible tablet described herein allows for a rapidly disintegration of the tablet that results in a flocculent suspension once the dispersible tablet is added to liquid for administration.

Methods

[0231] The tablets described herein are useful for the treatment of conditions associated with oxygen deficiency in a patient in need thereof and regardless of the âge of the patient. Provided herein are methods of increasing affmity of hemoglobin for oxygen in a patient. In one embodiment, the methods comprise administering to the patient in need thereof a tablet described herein comprising a therapeutically effective amount of Compound 1. In one embodiment, the therapeutic amount of Compound 1 is from 600 mg to 2000 mg per day. In another embodiment, the therapeutic amount of Compound 1 is 600 mg. In another embodiment, the therapeutic amount of Compound 1 is 900 mg. In another embodiment, the therapeutic amount of Compound 1 is 1500 mg. In some embodiments, the therapeutic amount of Compound 1 is from 50 mg to 2000 mg per day. In some embodiments, the therapeutic amount of Compound 1 is from 50 mg to 1500 mg per day. In one embodiment, the therapeutic amount of Compound 1 is from 900 mg to 1500 mg per day. In one embodiment, the therapeutic amount of Compound 1 is from 600 mg to 1200 mg per day. In one embodiment, the therapeutic amount of Compound 1 is from 600 mg to 900 mg per day. In another embodiment, the methods comprise administering to the patient in need thereof a tablet described herein, wherein the tablet comprises about 900 mg to about 1500 mg of Compound 1. In another embodiment, the methods comprise administering to the patient in need thereof a tablet described herein, wherein the tablet comprises about 300 mg to 900 mg of Compound 1. In another embodiment, the methods comprise administering to the patient in need thereof a tablet described herein, wherein the tablet comprises about 300 mg of Compound 1 and wherein the administration is 1 to 5 times daily. In another embodiment, the methods comprise administering to the patient in need thereof a tablet described herein, wherein the tablet comprises about 300 mg of Compound 1 and wherein the patient is simultaneously administered 1 to 5 tablets. In another embodiment, the methods comprise administering to the patient in need thereof a tablet described herein, wherein the tablet comprises about 900 mg of Compound 1 and wherein the administration is once daily.

[0232] Also provided herein are methods of increasing affinity of hemoglobin for oxygen in a patient, wherein the patient is about 9 months old to about 11 years old. In one embodiment, the methods comprise administering to the patient in need thereof a tablet described herein comprising a therapeutically effective amount of Compound 1. In some embodiments, the tablet is mixed with an appropriate vehicle, such as food, prior to administration. In such embodiments, the tablet is crushed, mixed with food, and subsequently administered to the patient. In some embodiments, the therapeutic amount of Compound 1 is from 50 mg to 2000 mg per day. In one embodiment, the therapeutic amount of Compound 1 is from 600 mg to 2000 mg per day. In some embodiments, the therapeutic amount of Compound 1 is from 50 mg to 1500 mg per day. In some embodiments, the therapeutic amount of Compound 1 is from 100 mg to 600 mg per day. In one embodiment, the therapeutic amount of Compound 1 is from 600 mg to 900 mg per day. In another embodiment, the therapeutic amount of Compound 1 is 600 mg. In another embodiment, the therapeutic amount of Compound 1 is 900 mg. In another embodiment, the therapeutic amount of Compound 1 is 1500 mg. In another embodiment, the methods comprise administering to the patient in need thereof a tablet described herein, wherein the tablet comprises about 100 mg to 600 mg of Compound 1. In another embodiment, the methods comprise administering to the patient in need thereof a tablet described herein, wherein the tablet comprises about 100 mg to 300 mg of Compound 1. In another embodiment, the methods comprise administering to the patient in need thereof a tablet described herein, wherein the tablet comprises about 100 mg of Compound 1 and wherein the administration of the tablet is 1 to 9 times daily. In another embodiment, the methods comprise administering to the patient in need thereof a tablet described herein, wherein the tablet comprises about 300 mg of Compound 1 and wherein the administration of the tablet is 1 to 3 times daily. In another embodiment, the methods comprise administering to the patient in need thereof a tablet described herein, wherein the tablet comprises about 100 mg of Compound 1 and wherein the patient is simultaneously administered 1 to 9 tablets. In another embodiment, the methods comprise administering to the patient in need thereof a tablet described herein, wherein the tablet comprises about 300 mg of Compound 1 and wherein the patient is simultaneously administered 1 to 3 tablets.

' [0233] Also provided herein are methods of increasing affinity of hemoglobin for oxygen in a patient, wherein the patient is about 9 months old to about 11 years old. In one embodiment, the methods comprise administering to the patient in need thereof a dispersible tablet described herein comprising a therapeutically effective amount of Compound 1. In some embodiments, the dispersible tablet is dissolved in a liquid prier to its administration to the patient. In some embodiments, the dispersible tablet is added to a liquid to be dispersed prior to its administration to the patient. In some embodiments, the liquid is water or other drink for consumption. In some embodiments, the dispersible tablet is dissolved in a liquid (for example, in a cup) prior to its administration to the patient, the liquid is administered to the patient, and the cup further rinsed with additional liquid, which is also administered to the patient. In 10 some embodiments, the therapeutic amount of Compound 1 is from 50 mg to 2000 mg per day. In one embodiment, the therapeutic amount of Compound 1 is from 600 mg to 2000 mg per day. In some embodiments, the therapeutic amount of Compound 1 is from 100 mg to 600 mg per day. In one embodiment, the therapeutic amount of Compound 1 is from 600 mg to 900 mg per day. In another embodiment, the therapeutic amount of Compound 1 is 600 mg. In another embodiment the therapeutic 15 amount of Compound 1 is 900 mg. In another embodiment the therapeutic amount of Compound 1 is

1500 mg. In another embodiment, the methods comprise administering to the patient in need thereof a tablet described herein, wherein the tablet comprises about 100 mg to 600 mg of Compound 1. In another embodiment, the methods comprise administering to the patient in need thereof a tablet described herein, wherein the tablet comprises about 100 mg to 300 mg of Compound 1. In another embodiment, the methods comprise administering to the patient in need thereof a tablet described herein, wherein the tablet comprises about 100 mg of Compound 1 and wherein the administration of the tablet is 1 to 9 times daily. In another embodiment, the methods comprise administering to the patient in need thereof a tablet described herein, wherein the tablet comprises about 300 mg of Compound 1 and wherein the administration of the tablet is 1 to 3 times daily. In another embodiment, the methods comprise administering to the patient in need thereof a tablet described herein, wherein the tablet comprises about 100 mg of Compound 1 and wherein the patient is simultaneously administered 1 to 9 tablets. In another embodiment, the methods comprise administering to the patient in need thereof a tablet described herein, wherein the tablet comprises about 300 mg of Compound 1 and wherein the patient is simultaneously administered 1 to 3 tablets.

[0234] Further provided herein are methods for treating a condition associated with oxygen deficiency in a patient. In one embodiment, the method comprises administering to the patient having a condition associated with oxygen deficiency; a tablet described herein comprising a therapeutically effective amount of Compound 1. In one embodiment, the condition is sickle cell disease, cancer, a pulmonary disorder such as interstitial pulmonary fibrosis, stroke, high altitude sickness, an ulcer, a pressure sore, acute respiratory disease syndrome, acute lung injury, or a wound. In one embodiment, the condition is sickle cell disease, cancer, a pulmonary disorder such as interstitial pulmonary fibrosis, stroke, high altitude sickness, an ulcer, a pressure sore, Alzheimer’s disease, acute respiratory disease syndrome, acute lung injury, or a wound. In one embodiment, the condition is sickle cell disease, cancer, ' a pulmonary disorder such as idiopathic pulmonary fibrosis, stroke, high altitude sickness, an ulcer, a pressure sore, Alzheimer’s disease, acute respiratory disease syndrome, acute lung injury, or a wound. In one embodiment, the condition is sickle cell disease. In one embodiment, the conditions is a pulmonary disorder. In one embodiment, the pulmonary disorder is interstitial pulmonary fibrosis. In one embodiment, the pulmonary disorder is idiopathic pulmonary fibrosis. In one embodiment, the therapeutic amount of Compound 1 is from 600 mg to 2000 mg once a day. In another embodiment, the therapeutic amount of Compound 1 is 600 mg. In another embodiment, the therapeutic amount of Compound 1 is 900 mg. In another embodiment the therapeutic amount of Compound 1 is 1500 mg.

[0235] In one embodiment, the therapeutically effective amount of Compound 1 is from 600 to 2000 10 mg once a day. In one embodiment, the therapeutically effective amount of Compound 1 is 900 mg or

1500 mg once a day. In one embodiment, the tablet contains 300, 750 or 900 mg of 2-hydroxy-6-((2-( 1 isopropyl-1 H-pyrazol-5-yl)pyridin-3 -yl)methoxy)benzaldehyde.

[0236] It is understood that modifications which do not substantially affect the activity of the various embodiments of this disclosure are also included within the définition of the disclosure provided herein. Accordingly, the following examples are intended to illustrate but not limit the présent disclosure.

EXAMPLES

Example 1: Compression profile of Form II of Compound 1

[0237] The compressibility of crystalline Form II of Compound 1 (“API”) was determined by compressing neat unformulated API at 200 mg scale compressed in a hydraulic press using 5/16^th inch diameter, standard concave round tooling. The resulting tablets were measured for thickness using a digital caliper gauge, and for tensile strength using a tablet hardness tester. Table 1 shows the results of this compressibility study using 3 samples of Form II of Compound 1 (Lots la, 1b, and 2). Lots la and 2 were directly from the API manufacturing process, but from different API suppliers. Lot 1b was prepared by taking Lot la and subjecting it to hammer milling to cause réduction of particle size.

Table 1

Compound 1 Form II API Lot #	Compression Force (Ibf)	Tablet Thickness (mm)	Tablet Hardness (kp)
la	2000	4.50	1.8
3000	4.34	1.5
4000	4.35	1.0
1b (hammer milled lot la)	2000	4.55	2.4
3000	4.32	1.2
4000	4.43	1.5
2	2000	4.50	9.0
3000	4.27	3.7
4000	4.31	3.4

[0238] The compression profiles in Table 1 indicate low tablet hardness and that Form II of

Compound 1 is a relatively incompressible solid. The implication of this is that compression of neat API does not achieve a tensile strength relevant for pharmaceutical tablet manufacture. Further, Form II of Compound 1 exhibits a fiat or slightly négative response of hardness resulting from increasing compressive force. Hence compression at higher forces doesn’t enable higher tensile strength tablets to be manufactured. Consequently neat API tablets would hâve weak integrity and be overly friable, prone to crumbling during manufacturing process, packaging, transport and storage in bottle or blister States. Milling of one lot of API did not resuit in appreciably increased tablet hardness. Increasing compression force if anything, resulted in slight over compression (slightly decreasing hardness at higher compression 10 force). This may arise from breakage of crystals and agglomérâtes at higher tableting compression force.

Overall, the Form II of Compound 1 compression profile is not acceptable as a neat API and requires formulation with excipients to overcome poor compression properties.

Example 2: Formulation and manufacture of Gl and G2 prototypes (lab scale)

[0239] Tablets of Form II of Compound 1 were prepared in 2 similar formulations: Gl and G2. G2 15 was compositionally the same as Gl, except it also contained 1.5% sodium lauryl sulfate in the extragranular phase, and a concurrent 1.5% decrease in the extragranular level of extragranular MCC filler. Tables 2 and 3 below give the compositions. The tablets were prepared using the following sequence of manufacturing steps:

[0240] Form II of Compound 1 was blended with the intragranular quantities of microcrystalline 20 cellulose and croscarmellose sodium, and then further blended with the intragranular quantity of magnésium stéarate. The powder pre-blend was dry granulated by roller compaction, and then milled to produce granules. The granules were blended with the extragranular quantities of microcrystalline cellulose, croscarmellose sodium, and sodium lauryl sulfate (for G2 only), and then further blended with the extragranular quantity of magnésium stéarate. The final blend was compressed into tablets using a 25 tablet press.

Table 2: Composition of Gl Formulation of Form II of Compound 1 Tablets at 300 mg and 100 mg Strengths

Ingrédient	Grade	Conc. (%w/w)	Unit Weight (mg/tablet)	Unit Weight (mg/tablet)	Function
Intragranular
Compound 1 Form II, API	N/A	60.00	300.00	100.00	Active
Microcrystalline Cellulose	Ceolus™ UF- 711	27.50	137.50	45.83	Filler
Croscarmellose Sodium	Ac-Di-Sol® SD-711	1.00	5.00	1.67	Disintegrant
Magnésium Stéarate	Ligamed MF-2-V	1.50	7.50	2.50	Lubricant
Extragranular

Microcrystalline Cellulose	Ceolus™ UF711	9.00	45.00	15.00	Filler
Croscarmellose Sodium	Ac-Di-Sol® SD-711	0.25	1.25	0.42	Disintegrant
Magnésium Stéarate	Ligamed MF-2-V	0.75	3.75	1.25	Lubricant
	Total	100%	500 mg	167 mg

Table 3: Composition of G2 Formulation of Form II of Compound 1 Tablets at 300 mg and 100 mg Strengths

Ingrédient	Grade	Conc. (%w/w)	Unit Weight (mg/tablet)	Unit Weight (mg/tablet)	Function
Intragranular
Compound 1 Form II, API^a	N/A	60.00	300.00	100.00	Active
Microcrystalline Cellulose³	Ceolus™ UF-711	27.50	137.50	45.83	Filler
Croscarmellose Sodium	Ac-Di-Sol® SD-711	1.00	5.00	1.67	Disintegrant
Magnésium Stéarate	Ligamed MF-2-V	1.50	7.50	2.50	Lubricant
Extragranular
Microcrystalline Cellulose	Ceolus™ UF-711	7.50	37.50	12.50	Filler
Croscarmellose Sodium	Ac-Di-Sol® SD-711	0.25	1.25	0.42	Disintegrant
Sodium Lauryl Sulfate	Kolliphor® SLS Fine	1.50	7.50	2.50	Surfactant
Magnésium Stéarate	Ligamed MF-2-V	0.75	3.75	1.25	Lubricant
	Total	100%	500 mg	167 mg

Example 3: Accelerated stability testing of G1 and G2 prototypes

[0241] Tablets of G2 were tested for stability at stressed storage conditions to accelcrate stability testing. 100 mg G2 tablets were packaged in high density polyethylene bottles, and induction sealed with a aluminum foil faced lined cap. The bottles were stored in an environmental chamber at 40 °C, 75% relative humidity (RH), and also in a chamber at 25 °C, 60% RH to replicate ICH (International Conférence on Harmonization) storage conditions. The tablets were tested at time zéro and post 1 month of storage for appearance, assay, impurities, and dissolution properties. Table 4 summarizes the stability results.

Table 4: Stability data of Form II of Compound 1 tablets, 100 mg strength

Stability Condition	Storage Time	Appearance	Assay	Total Impurities	Dissolution (% released at 60 min)
25°C / 60%	Time zéro	Off-white tablets	96.0%	< 0.05%	98
RH	1 month	Off-white tablets	96.3%	< 0.05%	102

40°C / 75%	Time zéro	Off-white tablets	96.0%	< 0.05%	98
RH	1 month	Off-white tablets	96.4%	< 0.05%	98

[0242] The stability data demonstrates there were no significant changes in appearance, no loss of assay, no growth in impurities or dégradants, and complété dissolution release within experimental limits. Therefore G2 tablet has good stability characteristics with no gross Chemical incompatibilities between Form II of Compound 1 and the composite excipients. Since the 300 mg and higher strengths of Form II 5 of Compound 1 G2 tablets are made using a common blend, the stability properties of the 100 mg strength tablet are représentative of ail strengths, such as 300 - 900 mg strengths.

Example 4: In vitro dissolution testing of G1 and G2 prototype formulations

[0243] A dissolution study was conducted to compare the G1 and G2 tablet formulations and a formulated capsule product. This used a USP paddle dissolution apparatus and method. Each of six dissolution vessels was filled with 900 mL of dissolution media, including 0. IN hydrochloric acid, and 0.5% Tween 80 surfactant; the paddle was rotated at 75 RPM, and the extent of release was determined by concentration measurements at a UV absorbance détection wavelength of 345 nm. The compositions of the capsule shells; Compound 1, Form II Capsules; and Compound 1, Form II Common Placebo Capsules are given in Tables 5, 6, and 7, respectively. The dissolution profiles are given in FIG. 1. The

G2 tablet formulation was tested at both uncoated State (100 mg) and film coated higher strength State (300 mg).

Table 5: Composition of the capsule shell

Component	Function	Reference to Standards
HPMC (hypromellose)	Structure	(EU) 231/2012, Ph. Eur., JP, USP/NF
Red iron oxide	Colorant	(EU) 231/2012, 21 CFR, JPE, USP/NF
Titanium dioxide	Opacifier	(EU) 231/2012, 21 CFR, Ph. Eur., JP, USP/NF

NF = National Formulary; Ph. Eur. = European Pharmacopoeia; USP = United States Pharmacopeia; JP = Japanese Pharmacopoeia

Table 6: Quantitative Composition of Compound 1, Form II Capsules (300 mg)

Components	Quantity (%w/w)	Quantity (mg/capsule)	Function	Reference to Standard or similar
Compound 1 Form II, Unmilled	85.71	300.00	Drug substance	In-house
Hydroxypropyl methylcellulose (Methocel® E5 Premium LV)	4.00	14.00	Binder	USP
Microcrystalline Cellulose (Avicel® PH-101)	3.64	12.74	Filler	NF
Lactose Monohydrate (Foremost Grade 310)	2.65	9.28	Filler	NF
Croscarmellose Sodium (Ac-Di-Sol®)	3.50	12.25	Disintegrant	Ph. Eur./NF
Stérile Water for Irrigation³	N/A	N/A	Granulation Liquid	USP
Magnésium Stéarate (Hyqual®, Vegetable Source)	0.50	1.75	Lubricant	NF
Total Fill Weight	100.00	350.02	-	-
HPMC (hydroxypropyl methylcellulose (hypromellose)), Swedish orange opaque, Vcaps® Plus Coni-Snap, capsules, size 0	N/A	96.0	Capsule shell	USP/NF, Ph.Eur.
Total Weight	N/A	446.02	-	-

[0244] The composition of the Compound l, Form II Common Placebo Capsules is provided below in Table 7 below.

Table 7: Composition of Compound 1, Form II Common Placebo Capsules

Components	Composition per Capsule (mg)	Function	Reference to Standards
Microcrystalline cellulose *	298.5	Bulking Agent	NF, Ph. Eur., JP
Magnésium Stéarate, NF	1.5	Lubricant	NF, Ph. Eur.
HPMC (hydroxypropylmethylcellulose (hypromellose)), Swedish orange opaque, Vcaps® Plus Coni-Snap, capsules, size 0	1 unit (96 mg)	Capsule shell	Supplier’s inhouse

# Avicel pH-102, or équivalent

[0245] The dissolution data (FIG. 1) shows that the G1 and G2 tablet formulations each achieved pharmaceutically useful release consistent with immédiate release profile products. The G2 formulation is superior to G1 in that it achieves the most rapid and complété release profile compared to G1 and to the capsule product. This indicates that the SLS surfactant in G2 is assisting in the release of Form II of Compound 1 from the highly compacted tablet State in order to replicate the release observed from the non-compressed State in capsules, and with a more rapid rate of release. Further, the capsule product had been historically used in clinical trials where doses in the range of 300 - 900 mg hâve demonstrated efficacy in treating patients suffering SCD. Therefore this data is confirming that the SLS surfactant is a surprisingly useful functional excipient in order to make pharmaceutically useful tablets of Compound 1 Form II as shown in the dissolution profile as compared to Formulation Gl. Formulation G1 in vivo also showed a reasonable bioavailability profile. This data also shows that the G2 tablet formulation has release properties by USP dissolution methods that are independent of tablet strength as well as independent of film coating versus uncoated tablet cores.

Example 5: In vivo absorption study (dog PK) of Gl and G2 formulations and capsule products

[0246] A beagle dog oral delivery study was performed to assess the absorption characteristics of the Gl and G2 tablets, and compared to the capsule product. Each prototype was prepared at 100 mg strength. Table 8 summarizes the results of this study. The bioavailability relative to the capsule product was calculated on a relative basis to compare the systemic exposure of Gl and G2 tablets to the capsules.

Table 8

Product	Cmax (CV%) (pg/mL)	AUC (CV%) (h. pg/mL)	Bioavailability relative to capsule
G1 tablet - 100 mg	7.80 (56.7)	650 (31.0)	83.3%
G2 tablet - 100 mg	8.25 (19.9)	770 (21.8)	101.9%

CV% is the coefficient of variation expressed as a percentage

[0247] The pharmacokinetic data reveals that in vivo the G l and G2 tablets hâve pharmaceutically 5 useful absorption characteristics. Surprisingly, and consistent with the dissolution behavior, the G2 formulation of tablets exhibited an exposure équivalent to the capsules, which had previously demonstrated human clinical efficacy in treating SCD in the dose range of 300-900 mg. It is very useful that the G2 tablets (containing 1.5% SLS surfactant) are able to achieve comparable systemic exposure, despite having been subjected to high mechanical compression force. This enables Form II of Compound 10 1 to be provided in significantly higher doses per unit tablet (versus per capsule), and without any loss in extent of release or absorption. What is further surprising is that the SLS surfactant demonstrates a réduction in the variability of Cmax and AUC PK parameters. Reducing variability of Cmax is particularly useful for managing potential side effects, which are frequently found to be more extreme at the Cmax State where exposure concentration is at its peak. By reducing variability of Cmax, the risk of 15 some patients experiencing Cmax related toxicities is reduced and thereby G2 is a more biopharmaceutically robust product. Variability in Cmax after capsule dosing in the same beagle dogs was observed at 31.5% and 50.1%. Despite the function of SLS being a surfactant to aid wetting of powder in aqueous media, SLS was observed here to be very useful in reducing variability of Cmax which has benefits for the overall safety and toxicity profile of Compound 1. Likewise, the AUC exposure was reduced to a very favorably low level of variability in the G2 tablet product, with CV% = 21.8%. The capsule product in these beagle dogs showed variability on AUC of 30.4%, and 52.2%.

Therefore both G1 and G2 tablets exhibited less variability in AUC exposure than capsules, and in fact the G2 tablet formulation showed the least variability across these products. A CV% of 21.8% is favorably low in a beagle dog study and further supports the pharmaceutical utility of both the G1 and G2 25 tablet formulations.

Example 6: Production of G2 tablet product at 5 kg batch scale

[0248] The G2 tablet formulation at 300 mg strength was scaled up to 5.720 kg batch size and run under GMP conditions to manufacture clinical trial tablets of Form II of Compound 1. Per the process described stepwise in example 3a, 3.3kg of Form II of Compound 1 and the corresponding quantities of 30 intragranular excipients excluding magnésium stéarate were blended in a V-shell blender at a blend speed of 25 rpm, and blend time of 10 minutes. This pre-mix was passed through a co-mill at 655 rpm to ensure any agglomérâtes were broken to free flowing powder. The intragranular magnésium stéarate was added, ' and the pre-blend was further blended in the V-shell blender at 25 rpm for 3 minutes. The pre-blend was processed in a roller compactor at a gap width target of 1.5 mm, 3.5 kN/cm force, and roll speed of 3rpm. Ribbon compacts were milled to granules using a 1,00mm sized screen and granulator rotor.

Extragranular excipient were blended with the granules, excluding magnésium stéarate, for 25 rpm, 7 minutes. Then further blended with the extragranular quantity of magnésium stéarate for 3 minutes at 25 rpm.

[0249] Tablets were compressed from the final blend at a compression force of 18.6 kN, a precompression force of 1.6 kN, and a press speed of 20 rpm in a 9 station rotary tablet press. The tablets had an average hardness of 12.9 kp, exhibited very low or negligible friability (0.1% and 0.0% weight loss for 6.5g of tablets tumbled in a USP friabilator for 4 minutes). The tablets had rapid disintegration in 37 °C water (1min 4 seconds, and 1 minute 10 seconds) tested by the USP disintegration method.

[0250] The tablets were film coated with a cosmetic coating Opadry II coating system at a target rate of 15g/min coating suspension until a target film coating weight gain of 4% was achieved. The tablets were tested by validated analytical methods meeting ail product quality acceptance criteria, and released 15 for human clinical use.

Example 7: Compound 1 Tablets with Glidant

[0251] Tablets of Compound 1 Form II and a glidant were prepared according to the Examples provided herein. These tablets are summarized in Table 9a and 9b.

Table 9a: Composition of Form II of Compound 1 High Strength Tablets with Glidant

Component	Quantity	Unit Weight	Function
(%w/w)	(mg/tablet)
Intragranular
Compound 1 Form II	59.55	900.0	Active
Microcrystalline Cellulose	27.29	412.4	Filler
Croscarmellose Sodium	0.99	15.0	Disintegrant
Magnésium Stéarate³	1.49	22.5	Lubricant
Colloïdal Silicon Dioxide^b	0.49	7.5	Glidant
Extragranular
Microcrystalline Cellulose	7.44	112.4	Filler
Croscarmellose Sodium	0.25	3.8	Disintegrant
Sodium Lauryl Sulfate	1.49	22.5	Surfactant
Colloïdal Silicon Dioxide^b	0.75	11.3	Glidant
Magnésium Stearate^a	0.74	11.2	Lubricant
Core Total	100.48	1518.6	-
Film Coating (Color Coat)
Opadry II Yellow System	4.0^b	60	Cosmetic (color)
Coated Total	104.48	1578.6	-

^aFrom a vegetable source ^b The colloïdal Silicon dioxide component can be adjusted between intragranular and extragranular additions

Table 9b: Composition of Form II of Compound l High Strength Tablets with Glidant

Component	Quantity	Unit Weight	Function
(%w/w)	(mg/tablet)
Intragranular
Compound 1 Form II	59.55	900	Active
Microcrystalline Cellulose	27.0	408	Filler
Croscarmellose Sodium	1.0	15	Disintegrant
Magnésium Stearate^a	1.5	23	Lubricant
Colloïdal Silicon Dioxide^b	0.5	8	Glidant
Extragranular
Microcrystalline Cellulose	7.2	109	Filler
Croscarmellose Sodium	0.25	4	Disintegrant
Sodium Lauryl Sulfate	1.5	23	Surfactant
Colloïdal Silicon Dioxide^b	0.75	11	Glidant
Magnésium Stearate^a	0.75	11	Lubricant
Core Total	100.0	1512	-
Film Coating (Color Coat)
Opadry II Yellow System	4.0	60	Cosmetic (color)
Coated Total	104.00	1571	-

Example 8: Dispersible Tablets

[0252] Dispersible tablets of Form II of Compound 1 were prepared according to the Examples provided herein without the addition of a film coating.

[0253] Dispersible tablets having 300 mg or 900 mg of Form II of Compound 1 are summarized in Table 10.

Table 10: Compositions of Dispersible Tablets of Form II of Compound 1 at 300 mg and 900 mg Strengths

Component	Quantity	Unit Weight	Unit Weight	Function	Reference to Standard or similar
(%w/w)	(mg/tablet)	(mg/tablet)
Intragranular
Compound 1 Form II	58.45	300.0	900.0	Active
Microcrystalline Cellulose	26.30	135.0	405.0	Filler	USP/NF/Ph. Eur.
Croscarmellose Sodium	0.97	5.0	14.9	Disintegrant	USP/NF/Ph. Eur.
Magnésium Stéarate³	1.46	7.5	22.5	Lubricant	USP/NF/Ph. Eur.
Colloïdal Silicon Dioxide^b	0.49	2.5	7.5	Glidant	USP/NF/Ph. Eur.
Extragranular
Microcrystalline Cellulose	7.80	40.0	120.1	Filler	USP/NF/Ph. Eur.
Croscarmellose Sodium	0.25	1.3	3.8	Disintegrant	USP/NF/Ph. Eur.
Magnésium Stearate^a	0.73	3.7	11.2	Lubricant	USP/NF/Ph. Eur.
Sucralose	2.53	13.0	39.0	Sweetener	USP/NF/Ph. Eur.
Artificial Grape Flavor	0.54	2.8	8.3	Flavor	FEMA GRAS CFR
Iron Oxide Pigment	0.24	1.2	3.7	Colorant	NF, JPE, E172
Colloïdal Silicon Dioxide^b	0.24	1.2	3.7	Glidant	USP/NF/Ph. Eur.
Total	100.00	513.3	1539.8	-	-

[0254] Dispersible tablets having 50 mg or 100 mg of Form II of Compound 1 are summarized in

Table 11.

Table 11

Ingrédients	% w/w	mg/Tablets
50mg Strength	lOOmg Strength
Compound 1 Form II	58.45	50.00	100.00
Microcrystalline Cellulose	34.10	29.17	58.34
Croscarmellose Sodium	1.22	1.04	2.09
Magnésium Stéarate	2.19	1.87	3.75
Sucralose	2.53	2.16	4.33
Artificial Grape Flavor	0.54	0.46	0.92
Iron Oxide Yellow Pigment	0.24	0.21	0.41
Colloïdal Silicon Dioxide	0.73	0.62	1.25
Total	100.00	85.54	171.09

Example 9: Evaluation of Impact of Disintegrant Levels in Dispersible Tablets

[0255] One of the salient features of a dispersible tablet is to hâve a rapid dispersion time in a small 5 volume of solution, in addition to having other standard tablet characteristics, such as tablet hardness and friability, within an acceptable range. Tablet hardness and friability are also important because high friability in tablets leads to breakage in tablets during processing, packaging and transportation.

Typically, hardness is directly proportional to dispersion time, but indirectly proportional to friability within a certain range. In order to achieve rapid dispersion times with acceptable tablet hardness and 10 friability, dispersible tablets typically include higher percentage of disintegrants (also called a superdisintegrant and generally in the range of 5 to 20% w/w) compared to standard, non-dispersible tablets. Surprisingly, as shown in Table 12, a dispersible tablet having only 1.25% w/w croscarmellose sodium displayed superior dispersion characteristics (i.e. rapid disintegration times) with dispersion times of less than 60 seconds, while maintaining acceptable tablet hardness and friability.

[0256] The impact of disintegrant levels in dispersible tablets of Compound 1 with increasing amounts of croscarmellose sodium was evaluated, and the results are summarized in Table 12. The dispersible tablets at 300 mg strength (and compressed at 2500 psi using a manual tablet press) used for these studies are also summarized in Table 12. These tablets were prepared as follows.

[0257] A dry granulation process using a roller compactor was used for préparation of the tablet 20 blend and tablets were compressed using a manual tablet press.

• Pre-Blending: Ail the intragranular excipients were weighed out and sieved to remove any agglomérâtes.

• Roller Compaction (Dry Granulation) and Milling: The pre-blend (intragranular) was then passed through a small-scale bench top roller compactor and a mill to obtain the granulation (intragranular portion) blend.

’ · Final Blend: The extragranular components were weighed and sieved to remove any agglomérâtes. The intragranular and the extragranular components were then mixed together using a small-scale bench top bottle blender to obtain the final blend (common blend) for compression into tablets.

· Tablet Compression: 300mg Dispersible Tablets were prepared with the final blend using a manual tablet press. Compressed tablets were evaluated for tablet hardness, thickness, friability and dispersion time.

[0258] Tablet characterization were performed as follows:

• Tablet Hardness and Thickness: Tablet hardness or tablet breaking force as per United States

Pharmacopoeia (“USP”) is the measure of the mechanical integrity of tablets. Tablet hardness, along with the thickness, was measured using a standard hardness tester as described in the USP.

• Tablet Friability: As per USP, tablet friability is a test of the ability of tablets to withstand mechanical stresses that détermines their résistance to chipping and surface abrasion by tumbling them in a rotating cylinder. The percentage weight loss after tumbling is referred to as the friability of the tablets. Tablet friability for Compound 1 tablets were tested using a friability tester designed as per USP spécifications.

• Dispersion Time: This study simulâtes a possible administration method of dispersible tablets to a patient. The method involves adding a dispersible tablet in a premeasured amount of water in a plastic dosing cup. Water is absorbed into the tablet and disintegrates rapidly to form a fine dispersion; the time taken for the tablet to completely disperse in the water (without any hard tablet aggregates or unmoistened tablet core) is the dispersion time.

Table 12

Ingrédients (% w/w in Tablet Formulation)	0% Ac-DiSol®	0.625% w/w Ac-DiSol®	1.25% w/w Ac-DiSol®	2.7% w/w Ac-DiSol®	5.3% w/w Ac-DiSol®	5% w/w Ac-DiSol® (4% IG, 1% EG)
Microcrystalline Cellulose	34	34	35	34	33	31.0
Croscarmellose Sodium (Ac-Di-Sol®)	0	1	1	3	5	5.0
Ratio	0	54	28	13	6	6

300mg Dispersible Tablets Compressed at 2500 psi Force using Manual Tablet Press
Dispersion Time (Sec) 5 mL Water	>300	57	35	28	35	37
Tablet Hardness	13	13	13	13	12	15

(kp)
Friability (%)	ND	ND	0.22	0.23	0.19	0.24

IG: Intragranular Portion; EG: Extragranular Portion; ND: Not Determined

[0259] As shown in Table 12, at 0% croscarmellose sodium, the tablets took more than 5 minutes to disperse, and the quality of the dispersion (observed visually) was also poor. It is contemplated that the 5 larger particles of these tablets can potentially impact the mouthfeel after administration, such as producing an unpleasant mouthfeel, which would then negatively impact a patient’s compliance of a dosing regimen.

[0260] As the percentage of croscarmellose sodium was increased from 0% to 0.625% w/w of the tablet, the dispersion time showed significant improvement. A fine dispersion (as observed visually) was 10 formed in less than 60 seconds. It is contemplated that these fine dispersed particles would produce less mouthfeel, which would thus enhance a patient’s compliance of a dosing regimen.

[0261] This data demonstrates the uniqueness of the dispersible tablets described herein; specifically, even with a small amount of crosscarmellose sodium (for example, 0.625% w/w of the tablet), a significant improvement in the dispersion time and quality of dispersion was observed.

[0262] As shown in Table 12, a dispersible tablet with 1.25% w/w croscarmellose sodium displayed superior dispersion characteristics (i.e. rapid disintegration times) with dispersion times of less than 60 seconds while having acceptable tablet hardness and friability.

[0263] It is interestingly noted that no further improvement in the dispersion time was observed as the percentage of croscarmellose sodium was increased from 1.25% to up to 5.3% w/w. This data 20 demonstrates that, unlike typical dispersible tablets, the dispersible tablets described herein do not require a high quantity of crosscarmellose sodium. Consequently, a désirable quantity of the filler (such as microcrystalline cellulose) in the tablets can be maintained for tablet hardness and friability.

[0264] As shown in Table 12, there was no impact from the addition of the disintegrant either as an intragranular or extragranular component.

[0265] Although the invention has been described with reference to the disclosed embodiments, those skilled in the art will readily appreciate that the spécifie examples and studies detailed above are only illustrative of the invention. It should be understood that various modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the following 30 claims.

Claims

WHAT IS CLAIMED IS:

1. A tablet comprising about 50% to about 70% by weight of 2-hydroxy-6-((2-( 1 -isopropy 1lH-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde and a microcrystalline cellulose as a filler provided that at least one microcrystalline cellulose is a high-compactable microcrystalline cellulose and wherein the % by weight is relative to the total weight of the tablet.
2. The tablet of claim 1, wherein the amount of 2-hydroxy-6-((2-( 1 -isopropyl-1 H-pyrazol-5yl)pyridin-3-yl)methoxy)benzaldehyde comprises from about 50% to about 65% by weight of the tablet.
3. The tablet of claim 1, wherein 2-hydroxy-6-((2-(l-isopropyl-lH-pyrazol-5-yl)pyridin-3yl)methoxy)benzaldehyde comprises about 65% by weight of the tablet.
4. The tablet of claim 1, wherein 2-hydroxy-6-((2-(l-isopropyl-lH-pyrazol-5-yl)pyridin-3yl)methoxy)benzaldehyde comprises about 60% ± 2% by weight of the tablet.
5. The tablet of any one of claims 1-4, wherein the high-compactable microcrystalline cellulose comprises from about 20% to about 40% by weight of the tablet.
6. The tablet of claim 5, wherein the high-compactable microcrystalline cellulose comprises about 30% by weight of the tablet.
7. The tablet of claim 5, wherein the high-compactable microcrystalline cellulose comprises 35% ± 2% by weight of the tablet.
8. The tablet of any one of claims 1-7, wherein the high-compactable microcrystalline cellulose is Ceolus™ UF-711.
9. The tablet of any one of claims 1-7, wherein the high-compactable microcrystalline cellulose is Ceolus™ KG-1000 or KG-802.
10. The tablet of any one of claims 1-9, wherein 2-hydroxy-6-((2-(l-isopropyl-lH-pyrazol-5yl)pyridin-3-yl)methoxy)benzaIdehyde is in a substantially pure crystalline ansolvate form characterized

W ⁶⁹ by at least two X-ray powder diffraction peaks (Cu Ka radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°20 (each ±0.2 °20).
11. The tablet of any one of claims 1 -9, consisting essentially of 2-hydroxy-6-((2-( 1 isopropyl-lH-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde as a crystalline ansolvate form

5 characterized by at least two X-ray powder diffraction peaks (Cu Ka radiation) selected from 13.37 , 14.37°, 19.95° and 23.92°2θ (each ±0.2 °2θ).
12. The tablet of claim 10 or 11, wherein the crystalline ansolvate form of 2-hydroxy-6-((2(1-isopropyl-lH-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde is characterized by at least three X-ray powder diffraction peaks (Cu Ka radiation) selected from 13.37°, 14.37 , 19.95 and 23.92 20 (each

10 ±0.2 °20).
13. The tablet of any one of claims 1-9, wherein the 2-hydroxy-6-((2-(l-isopropyl-lHpyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde comprises 95% by weight Form H characterized by Xray powder diffraction peaks (Cu Ka radiation) selected from 13.37°, 14.37°, 19.95 and 23.92 20 (each ±0.2 °20) and 5% by weight 2-hydroxy-6-((2-(l-isopropyl-lH-pyrazol-5-yl)-pyridin-3-

15 yl)methoxy)benzaldehyde is Form I and/or Form N.
14. The tablet of any one of claims 1-13, wherein the tablet further comprises a disintegrant from 0% to about 10% by weight of the tablet.
15. The tablet of claim 14, wherein the disintegrant comprises about 0.75% to about 1.5% by weight of the tablet.

20
16. The tablet of claim 14, wherein the disintegrant comprises about 1% to about 1.5% by weight of the tablet.
17. The tablet of any one of claims 14-16, wherein the disintegrant is croscarmellose sodium.
18. The tablet of any one of claims 1-17, wherein the tablet further comprises a lubricant from about 1.75% to about 2.75% by weight of the tablet.
19. The tablet of claim 18, wherein the lubricant comprises about 2.0% to about 2.5% by weight of the tablet.
20. The tablet of claim 18 or 19, wherein the lubricant is magnésium stéarate.
21. The tablet of any of claims 1 -20, wherein the tablet comprises from about 300 mg to about 900 mg of 2-hydroxy-6-((2-(l-isopropyl-lH-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde.
22. The tablet of any of claims 1-20, wherein the tablet comprises 300 mg of 2-hydroxy-6((2-( 1 -isopropyl-1 H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde.
23. The tablet of any one of claims 1-22, wherein the tablet further comprises a surfactant from about 1% to about 2% by weight of the tablet.
24. The tablet of claim 23, wherein the surfactant comprises about 1.5% by weight of the tablet.
25. The tablet of claim 23 or 24, wherein the surfactant is sodium lauryl sulfate.
26. A tablet comprising a granular component wherein the granular component comprises:

(i) about 60% by weight of 2-hydroxy-6-((2-(l-isopropyl-lH-pyrazol-5-yl)pyridin-

3-yl)methoxy)benzaldehyde;

(ii) a high-compactable microcrystalline cellulose;

(iii) optionally a disintegrant;

(iv) a lubricant;

(v) optionally a surfactant; and (vi) optionally a binder;

wherein the percentage by weight is relative to the total weight of the tablet.
27. The tablet of claim 26, wherein the granular component comprises:

(i) a high-compactable microcrystalline cellulose in the amount of about 27.50% by weight of the tablet;

(ii) a disintegrant in the amount of about 1 % by weight of the tablet;

(iii) a lubricant in the amount of about 1.50% by weight of the tablet; and (iv) optionally a surfactant in the amount of about 1.5% by weight of the tablet.
28. The tablet of claim 27, wherein the high-compactable microcrystalline cellulose is Ceolus™ UF-711; the disintegrant is croscarmellose sodium; the lubricant is magnésium stéarate; 2hydroxy-6-((2-(l-isopropyl-lH-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde is a substantially pure crystalline ansolvate form characterized by at least two X-ray powder diffraction peaks (Cu Ka radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°2θ (each ±0.2 °20); and the surfactant is absent.
29. A tablet comprising a granular component wherein the granular component consists essentially of:

(i) about 60% by weight 2-hydroxy-6-((2-(l-isopropyl-lH-pyrazol-5-yl)pyridin-3- yl)methoxy)benzaldehyde;

(ii) a high-compactable microcrystalline cellulose;

(iii) optionally a disintegrant;

(iv) a lubricant;

(v) optionally a surfactant; and (vi) optionally a binder;

wherein the percentage by weight is relative to the total weight of the tablet.
30. The tablet of claim 29, wherein:

(i) the amount of high-compactable microcrystalline cellulose is about 27.50% by weight of the tablet;

(ii) the amount of disintegrant is about 1% by weight of the tablet;

(iii) the amount of lubricant is about 1.50% by weight of the tablet; and (iv) optionally, the amount of surfactant is about 1.5% by weight of the tablet.
31. The tablet of claim 30, wherein the high-compactable microcrystalline cellulose is

Ceolus™ UF-711; the disintegrant is croscarmellose sodium; the lubricant is magnésium stéarate; 2hydroxy-6-((2-(l-isopropyl-lH-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde is a substantially pure crystalline ansolvate form characterized by at least two X-ray powder diffraction peaks (Cu Ka radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°2θ (each ±0.2 °20); and the surfactant is absent.
32. The tablet of any one of claims 26-31, further comprising an extragranular component.
33. The tablet of claim 32, wherein the extragranular component comprises:

(i) a microcrystalline cellulose;

(ii) a disintegrant;

(iii) optionally a surfactant;

(iv) a lubricant; and (v) optionally a coating;

provided that at least one of the intragranular or extragranular components of the tablet comprises a surfactant.
34. The tablet of claim 33, wherein:

(i) the amount of extragranular microcrystalline cellulose comprises about 7.50% by weight of the tablet;

(ii) the amount of extragranular disintegrant comprises about 0.25% by weight of the tablet;

(iii) the amount of extragranular surfactant comprises about 1.50% by weight of the tablet; and (iv) the amount of extragranular lubricant comprises about 0.75% by weight of the tablet.
35. The tablet of claim 34, wherein the extragranular microcrystalline cellulose is highcompactable microcrystalline cellulose, the extragranular disintegrant is croscarmellose sodium, the extragranular lubricant is magnésium stéarate; and the extragranular surfactant is présent and is sodium lauryl sulfate.
36. The tablet of claim 35, wherein the high-compactable microcrystalline cellulose is Ceolus™ UF-711.
37. The tablet of claim 32, wherein the extragranular component consists essentially of:

(i) a microcrystalline cellulose;

(ii) a disintegrant;

(iii) optionally a surfactant;

(iv) a lubricant; and (v) optionally a coating;

provided that at least one of intragranular or extragranular component of the tablet contains a surfactant.
38. The tablet of any of claims 26-37, wherein the tablet comprises from about 300 to about 900 mg of 2-hydroxy-6-((2-(l-isopropyl-lH-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde.
39. The tablet of claim 38, wherein the tablet comprises 300 mg of 2-hydroxy-6-((2-(lisopropyl-lH-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde.
40. The tablet of claim 38, wherein the tablet comprises 900 mg of 2-hydroxy-6-((2-( 1 isopropyl-lH-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde.
41. The tablet of any one of claims 1-40, further comprising a glidant in an amount of less than about 2% by weight of the tablet.
42. The tablet of claim 41, wherein the glidant is in an amount of about 0.75% by weight of the tablet.
43. The tablet of claim 41 or 42, wherein the glidant is colloïdal Silicon dioxide.
44. A tablet comprising:

(i) an intragranular component comprising:

(a) 60% by weight of 2-hydroxy-6-((2-( 1 -isopropyl-1 H-pyrazol-5 - yl)pyridin-3-yl)methoxy)benzaldehyde as a crystalline form characterized by two, three or four X-ray powder diffraction peaks (Cu Ka radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°2Θ (each ±0.2 °20);

(b) 27.50% by weight of microcrystalline cellulose Ceolus™ UF-711 ;

(c) 1.0% by weight of Croscarmellose Sodium; and (d) 1.50% by weight of Magnésium Stéarate; and (ii) an extragranular component comprising:

(a) 9.0% by weight of microcrystalline cellulose Ceolus™ UF-711 ;

(b) 0.25% by weight of Croscarmellose Sodium; and (c) 0.75% by weight of Magnésium Stéarate;

wherein the percentage by weight is relative to the total weight of the tablet.
45. A tablet comprising:

(i) an intragranular component comprising:

(a) 60% by weight of 2-hydroxy-6-((2-(l-isopropyl-lH-pyrazol-5- yl)pyridin-3-yl)methoxy)benzaldehyde as a crystalline form characterized by two, three or four X-ray powder diffraction peaks (Cu Ka radiation) selected from 13.37°, 14.37°, 19.95° and 23.92°2θ (each ±0.2 °29);

(b) 27.50% by weight of microcrystalline cellulose Ceolus™ UF-711 ;

(c) 1.0% by weight of Croscarmellose Sodium; and (d) 1.50% by weight of Magnésium Stéarate; and (ii) an extragranular component comprising:

(a) 7.50% by weight of microcrystalline cellulose Ceolus™ UF-711 ;

(b) 0.25% by weight of Croscarmellose Sodium;

(c) 0.75% by weight of Magnésium Stéarate; and (d) 1.50% by weight Sodium Lauryl Sulfate;

wherein the percentage by weight is relative to the total weight of the tablet.
46. A dispersible tablet comprising:

(i) about 30% to about 70% by weight of Compound 1 ;

(ii) filler;

(iii) disintegrant;

(iv) glidant; and (v) a lubricant;

wherein the percentage by weight is relative to the total weight of the tablet.
47. A dispersible tablet comprising:

(i) about 30% to about 70% by weight of Compound 1;

(ii) a filler;

(iii) a disintegrant;

(iv) a glidant;

(v) a lubricant;

(vi) a surfactant; and (vii) optionally a binder;

wherein the amount of disintegrant to fdler is in a ratio of about 1:28, and wherein the percentage by weight is relative to the total weight of the tablet.
48. A tablet comprising:

(i) about 30% to about 70% by weight of Compound 1 ;

(ii) a filler;

(iii) less than about 2% by weight of disintegrant;

(iv) a glidant;

5 (v) a lubricant;

(vi) a surfactant; and (vii) optionally a binder;

wherein the amount of disintegrant to filler is in a ratio of about 1:28 and wherein the percentage by weight is relative to the total weight of the tablet.

10
49. A dispersible tablet comprising:

(i) about 60% by weight of Compound 1 Form Π;

(ii) about 20% to about 35% by weight of microcrystalline cellulose;

(iii) about 1% to about 2% by weight of croscarmellose sodium;

(iv) less than about 2% by weight of colloïdal Silicon dioxide;

15 (v) about 1% to about 5% by weight of magnésium stéarate;

(vi) a sweetener;

(vii) a flavoring agent; and (viii) a coloring agent;

wherein the percentage by weight is relative to the total weight of the tablet and wherein the dispersible

20 tablet disintegrates in a liquid in less than 1 minute.

β
50. A tablet comprising:

(i) about 50% to about 70% by weight of Compound 1 of formula:

ΙΟ (ii) about 30% to about 40% by weight of microcrystalline cellulose;

(iii) about 0.25% to about 3% by weight of croscarmellose sodium;

(iv) about 1 % to about 5% by weight of magnésium stéarate;

(v) about 0.5% to about 2.5% of sodium lauryl sulfate; and (vi) about 0.25% to about 5% by weight of colloïdal Silicon dioxide;

wherein the percentage by weight is relative to the total weight of the tablet.
51. The tablet of claim 50, comprising:

15 (i) about 35% by weight pf microcrystalline cellulose;

(ii) about 1.25% by weight of croscarmellose sodium;

(iii) about 2% by weight of magnésium stéarate; and (iv) about 1.5% by weight of sodium lauryl sulfate.
52. The tablet of claim 50, wherein the tablet comprises from about 300 to about 900 mg of 20 Compound 1.
53. The tablet of claim 50, comprising about 60% by weight of Compound 1.

77’
54. The tablet of claim 50, comprising about 35% by weight of microcrystalline cellulose.
55. The tablet of claim 50, comprising about 1.25% by weight of croscarmellose sodium.
56. The tablet of claim 50, comprising about 2% magnésium stéarate.
57. The tablet of claim 50, comprising about 1.5% of sodium lauryl sulfate.
58. The tablet of claim 50, wherein the tablet comprises from about 100 to about 600 mg of

Compound 1.
59. A tablet of any one of claims 1-49, wherein the tablet comprises a therapeutically effective amount of 2-hydroxy-6-((2-( 1 -isopropyl-1 H-pyrazol-5 -yl)pyridin-3 -yl)methoxy)benzaldehyde, for use in a method for treating a condition associated with oxygen deficiency in a patient.
60. The tablet for use of claim 59 or the use of claim 71, wherein the condition is sickle cell disease, cancer, a pulmonary disorder such as idiopathic pulmonary frbrosis, stroke, high altitude sickness, an ulcer, a pressure sore, Alzheimer’s disease, acute respiratory disease syndrome, acute lung injury, or a wound.
61. The tablet for use or the use of claim 60, wherein the condition is sickle cell disease.
62. The tablet for use or the use of claim 60, wherein the condition is a pulmonary disorder.
63. The tablet for use or the use of claim 60, wherein the condition is idiopathic pulmonary frbrosis.
64. The tablet for use or the use of any one of claims 59-62 or 71, wherein the therapeutically effective amount of 2-hydroxy-6-((2-(l-isopropyl-1 H-pyrazol-5-yl)pyridin-3-y l)methoxy)benzaldehy de is from 600 to 2000 mg once a day.
65. The tablet for use or the use of any one of claims 59-62 or 71, wherein the therapeutically effective amount of 2-hydroxy-6-((2-(l-isopropyl-lH-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde is 900 mg or 1500 mg once a day.
66. The tablet for use or the use of any one of claims 59-62 or 71, wherein the tablet contains

300, 750 or 900 mg of 2-hydroxy-6-((2-(l-isopropyl-lH-pyrazol-5-yl)pyridin-3yi)methoxy)benzaldehyde.
67. A tablet comprising:

5 (i) about 50% to about 70% by weight of Compound 1 of formula:

(ii) about 30% to about 40% by weight of microcrystalline cellulose;

(iii) about 0.25% to about 3% by weight of croscarmellose sodium;

(iv) about 1% to about 5% by weight of magnésium stéarate;

(v) about 0.5% to about 2.5% of sodium lauryl sulfate; and (vi) about 0.25% to about 5% by weight of colloïdal Silicon dioxide;

wherein the percentage by weight is relati ve to the total weight of the tablet, for use in a method of treating sickle cell disease in a patient.

15
68. The tablet for use of claim 67 or the use of claim 72, wherein the tablet comprises from about 300 to about 900 mg of Compound 1.
69. The tablet for use of claim 67 or the use of claim 72, wherein the patient is administered 900 mg or 1500 mg of Compound 1 once a day.
70. The tablet for use of claim 67 or the use of claim 72, wherein the tablet contains 300, 750

20 or 900 mg of Compound 1.
71. Use of 2-hydroxy-6-((2-( l-isopropyl-lH-pyrazol-5-yl)pyridin-3yl)methoxy)benzaldehyde in the manufacture of a tablet of any one of daims 1-49, wherein the tablet comprises a therapeutically effective amount of 2-hydroxy-6-((2-(l-isopropyl-lH-pyrazol-5-yl)pyridin-3yl)methoxy)benzaldehyde, for treating a condition associated with oxygen deficiency in a patient.
72. Use of

Compound 1 of formula:

in the manufacture of a tablet for treating sickle cell disease in a patient, wherein the tablet

10 comprises (i) about 50% to about 70% by weight of Compound 1;

(ii) about 30% to about 40% by weight of microcrystalline cellulose;

(iii) about 0.25% to about 3% by weight of croscarmellose sodium;

(iv) about 1% to about 5% by weight of magnésium stéarate;

15 (v) about 0.5% to about 2.5% of sodium lauryl sulfate; and (vi) about 0.25% to about 5% by weight of colloïdal Silicon dioxide;

wherein the percentage by weight is relative to the total weight of the tablet, for use in a method of treating sickle cell disease in a patient.